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Abstract 
This project addresses the complex relationship between the development of Rett Syndrome (RTT), 
and the normal function of the protein involved, Methyl-CpG Binding Protein 2 (MeCP2). RTT is a 
devastating neurological disorder showing first symptoms around the age of 6-12 months in the 
form of delayed motor skills and social withdrawal. Later, purposeful hand use is lost while 
stereotypic hand movements emerge and any obtained language is lost. The progression of RTT is 
perplexing because of this seemingly normal initial development and because of the loss of acquired 
speech. The gene involved in development of the disorder, MECP2, encodes a protein which has the 
ability of repressing transcription of certain genes. Through this project we wish to clarify the 
neuropathology of RTT in respect to normal function of MeCP2. With that aim, different RTT 
mouse models generated are studied. 
 
MeCP2 is important during maturation of neurons and for normal function of mature neurons. 
Genes that appear to be affected are involved in synapse- and dendrite development and mutated 
MECP2 results in reduced brain size, stunted neuronal connections, densely packed neurons, and 
diminished nuclei size. The symptoms of seizures and stereotypic hand movements are likely to be 
caused by elevated excitatory stimulation seen in young RTT patients. The decreased density of 
glutamate receptors that sets in around the age of eight years can explain the relative stabilization of 
phenotype around this time. The initial symptom of impaired locomotion is caused by disruption of 
serotonergic- and noradrenergic neurons in the brainstem. Further investigation is needed to clarify 
the cause of the distinct RTT symptoms and to understand the progression of disease. 
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Abstrakt 
Dette projekt omhandler det komplekse forhold mellem udviklingen af Rett syndrom (RTT) og 
funktionen af det involverede protein, Methyl CpG bindende protein 2 (MeCP2). RTT er en 
forfærdelig neurologisk sygdom som sætter ind omkring 6-12 måneders alderen og de tidlige 
symptomer er forsinkede bevægelsesfærdigheder og social tilbagetrækning. Senere ses også et tab 
af de almindelige målrettede håndbevægelser, hvorimod stereotypiske håndbevægelser fremtræder 
og erhvervet tale går tabt. Sygdomsforløbet af RTT er uforståelig pga. dens tilsyneladende 
indledende normale udvikling, samt tabet af den erhvervede tale. Genet som er involveret i 
udviklingen af sygdommen, MECP2, koder for et protein, som har evnen til at undertrykke 
transskription af visse gener. Gennem dette projekt ønsker vi at belyse neuropatologien af RTT i 
henhold til MeCP2s normale funktion. Med dette formål, er forskellige dannede RTT muse 
modeller undersøgt.  
         
MeCP2 har en vigtig betydning under modningen af neuroner og for deres normale funktion. Gener, 
der synes at blive påvirket, er involveret i synapse- og dendrit udviklingen. Muteret MECP2 
resulterer i nedsat hjerne størrelse, hæmmer neurale forbindelser, tæt pakker neuronerne og reducere 
neuroncellers kerne størrelse. Symptomer som anfald og stereotypiske håndbevægelser er 
sandsynligvis forårsaget af forhøjet exitatorisk stimulering som ses i unge RTT patienter. 
Reduceringen af densitet af glutamat receptorer, som ses omkring otte års alderen, kan forklare den 
relative stabilisering af fænotype omkring denne periode. Det første symptom af nedsat bevægelse 
er forårsaget af forstyrrelser i neuroner som benytter serotonin og noradrenalin som 
transmitterstoffer i hjernestammen. Yderligere undersøgelser er nødvendige for at klarlægge 
årsagen til de forskellige RTT symptomer og for at forstå sygdomsforløbet. 
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Preface 
 
This is a bachelor module project, composed in the autumn 2008, at Roskilde University. The 
project is a literary study with a molecular biological approach, which seeks to clarify the complex 
correlation between development of symptoms in RTT and mutations in the gene, MECP2, in 
respect to both the normal function of MeCP2 and the neuropathology of RTT.  
The project is constructed in two sections. The first section “Rett Syndrome” will give an 
understanding of the background knowledge of RTT and the disease-causing gene MECP2. This 
includes a presentation of the disease, its progression, and how the gene, MECP2 could be involved 
in development of the syndrome. The paragraph “Human Brain Development” is included to get an 
understanding of maturation of neurons and the development of synapses and dendrites which are 
impaired in RTT patients. This paragraph is followed by the second section “Correlation between 
Brain Development, Rett Syndrome, and MeCP2 expression”, which includes the paragraphs 
“Neuropathology of Rett Syndrome” and “RTT Mouse Models”. These concerns the morphology of 
RTT brains and the knowledge of MeCP2’s function obtained by using RTT mouse models, which 
make the foundation for the discussion. 
 
It will be possible to find a list of abbreviations in the beginning of the text. Additionally, the reader 
should be aware that when referring to a gene and its encoded protein different forms are used. The 
same is the case when distinguishing between human and murine genes and proteins. The general 
form is capital letters in italic form for human genes and without italics for the protein. Murine 
genes are in small letters and italic and the proteins are also in small letters but without italics. 
However a detailed description of writing form for every portrayed gene and protein is to be found 
in the aforementioned abbreviations. Furthermore definitions of certain words are provided in 
footnotes, and the appendix II is written on the basis of two books: [Widmaier et al. 2008] and 
[Seeley et al.,2008]  
 
The project is directed to researches, who work with Rett Syndrome, and others, with a molecular 
biological background, who are interested in the problem statement of the project. We would like to 
thank our supervisor Merete Rasmussen Assistant Professor at the department of science systems 
and models/NSM, and our external supervisor Kirstine Ravn, cand.scient. at the Kennedy Center - 
Center for Rett Syndrome, for  their competent guidance. 
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Abbreviations 
 
  
BDNF/BDNF   
Humans                  
Brain-derived neurotrophic factor/Gene  
Bdnf/Bdnf   
Mouse                  
Brain-derived neurotrophic factor/Gene  
cAMP Adenosine monophosphate  
CaRF Calcium-response factor 
CDKL5 Cyclin-dependent kinase-like 5  
1CMRG1c Local cerebral metabolic rates for glucose 
CNS Central nervous system 
CP Cortical plate 
CpG Cytosine/guanine with phosphodiester bond 
CREB Element binding protein 
CTR Carboxy-terminal region 
DA Dopamine 
DNA Deoxyribonukleinsyre 
DNMT DNA Methyltransferases 
EEG Elektroencefalografi 
GABA Gamma-aminobutyric acid   
HAT        Histone acetyltransferase 
HDAC Histone deacetylase 
5HT Serotonergic neurons 
MAP2 Microtubule-Associated Protein 2 
MBD/MBD              Methyl-CpG binding domain/Gene 
MeCP2/MECP2  
Humans 
Methyl-CpG binding protein 2/Gene 
Mecp2/Mecp2 
Mouse 
Methyl-CpG binding protein 2/Gene 
MGF Maintenance Growth Factors 
MRI Magnetic resonance imaging  
mRNA mRNA + gene 
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NA                    Noradrenergic 
NLS Localization signal sequence 
NMDA            N-methyl-D-aspartat 
NS                  Nervous system 
PCA Pchloroamphetamine 
PET Positron emission tomography 
PPN Pedunculopntine nucleus 
RNA Ribonucleic acid 
RTT Rett Syndrome 
TF Transcriptions factor 
TRD               Transcription repressor domain 
TSA Trichostatin A 
USF Upstream stimulatory factors 
VZ                  Ventricular zone  
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Introduction 
 
Rett Syndrome, also referred to as RTT, is a progressive neurological disorder, discovered in 1954 
by the Australian pediatrician Dr. Andreas Rett. In 1966 Dr. Rett published his work, but did not 
achieve worldwide recognition. First in 1983 the Swedish neurologist Dr. Hagberg and colleagues 
succeeded to draw the world’s attention to the newly discovered disorder and called it Rett 
Syndrome in honor of its pioneering researcher [International Rett Syndrome Foundation, 2008].  
The syndrome is found to be an X-linked disorder and therefore primarily occurs in females with an 
incidence of 1:10,000–1:15,000 worldwide. This high frequency makes it one of the most common 
causes of female mental retardation [Trevar, 1988; Jedele, 2007; Shahbazian & Zoghbi, 2002]. The 
few males that live with this gene defect often have an extra X-chromosome to compensate for the 
defect X-chromosome. Since the breakthrough in 1983 the syndrome has been studied intensively 
and clinical diagnostic criteria have been arrayed. In spite of this intense investigation no cure for 
the disorder has been found. The most common treatment of the disorder is symptom management 
for example in the form of physiotherapy-, occupational- and speech-language therapy. Also some 
medical treatment is used to reduce breathing problems and eliminate problems with heart beat 
rhythm [reviewed in NICHD, 2006]. In 1999 Amir and colleagues discovered an X-linked gene 
called MECP2 (Methyl-CpG Binding protein 2 gene) [Amir et al., 1999], which was mutated in 
approximately 70-90 % of the RTT patients [reviewed in Shahbazian et al., 2002B]. This discovery 
gives a deeper insight into RTT pathogenesis, and has already optimized the diagnoses and 
detection of the disorder in the form of blood tests if the syndrome is suspected. Further 
investigation into the function of this gene may eventually contribute to development of new 
treatment.    
The syndrome has a characteristic developmental progress, where the first 6-18 months of 
development appear normal, after which the symptoms of the syndrome emerge. The first sign of 
the syndrome is a delay of the normal developmental progress, which is followed by rapid 
developmental regression with loss of aquired skills. After the regression, some intermittent 
improvements occur. This stagnation period can last from few years to decades and after this the 
patients experience severe wasting and debilitation. [Shahbazian & Zoghbi, 2002; Renieri et al., 
2003; Jedele, 2007] The progression of the disorder seems puzzling because of the late onset of the 
syndrome as well as the loss of acquired skills. Therefore this project seeks to clarify the complex 
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relationship between the development of symptoms in classic RTT, and the role of MeCP2 in the 
neuropathology of the syndrome.  
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Method  
 
This project is a literature study dealing with the neurological disorder, RTT, and the associated 
protein MeCP2. The project includes paragraphs of basic knowledge about the pathology of RTT, 
the gene MECP2, the protein MeCP2 and neurology. This knowledge where obtained through 
scientific articles, which were found using keywords such as “Rett Syndrome", "RTT", "MeCP2", 
and “Epigenetics” in various scientific databases, which includes Medline and other websites, such 
as ASBMR, Google scholar, and SpringerLink. Some of the literature where also found with help 
from the project supervisors, Merete Rasmussen and Kirstine Ravn. In addition, the used literature 
includes physiological and anatomical textbooks. To answer the main topics, additional information 
where found in the aforementioned scientific databases and websites under the keyword "RTT 
mouse models", "Mutations in RTT" and "Neuronal development in RTT". Various components, 
especially the RTT mouse models, will be discussed in respect to the problem statement of the 
project.  
 
We strived to remain critical in collection of material, so recent review articles written after year 
2000 were mainly used. In addition original articles were primarily used. Original articles are 
defined as articles were a hypothesis has been verified experimentally for the first time. It was 
strived that more articles should be read on the same matter in order to get a broad overview of 
information and theories in relation to the project's problem statement. 
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1 Rett Syndrome 
 
Rett Syndrome is prominent in females because it is an X-linked disorder and thus often results in 
death among boys because they only possess one X-chromosome.  
To date, only few cases of MECP2 gene mutations in male have been detected [Mohammad et al., 
1999; Renieri et al., 2003]. However it is important to note that no evidence exists indicating that 
MECP2 mutations are lethal prenatally in male infants [Andrea et al., 2005]. Male MECP2 
mutations causes symptoms such as either encephalopathy
1
 with death at birth or X-linked recessive 
mental retardation and failure to survive after the first few days of extrauterine life [Renieri et al., 
2003, Andrea et al., 2005].  
 
Previous studies have made it possible to subdivide RTT into two broad categories: classic and 
variant (atypical) RTT. To establish clinical diagnose of classic and atypical RTT it has been 
possible to establish some criteria for how to diagnose and distinguish between these to categories. 
These criteria have been modified over time due to new studies where RTT children have been 
followed closely and their symptoms have been detected. After defining the criteria it became easier 
to understand the relationship between clinical, neurobiological, molecular and genetical 
characteristics of RTT [Hagberg et al., 2002]. The clinical criteria for classic and variant RTT are 
gathered in table 1 and 2 respectively.      
 
Table 1 Revised Diagnostic Criteria for Classic RTT [Jedele, 2007; Hagberg, 2002]                                                                                        
 
Necessary criteria 
1. Apparently normal prenatal and perinatal history 
2. Psychomotor development largely normal from 0 to 6 months, or delay from birth 
3. Normal head circumference at birth 
4. Postnatal deceleration of head growth in most cases 
5. Loss of purposeful hand skill between 6 and 30 months 
6. Stereotypic hand movements: wringing/squeezing, clapping, tapping, mouthing and rubbing 
7. Emerging social withdrawal, communication dysfunction, loss of learned words, and cognitive impairment 
8. Impaired (dyspraxic
2
) or failing locomotion 
 
Supportive criteria 
1. Awake disturbances of breathing: hyperventilation, breath holding, forced expulsion of air or saliva, air  
    swallowing 
2. Bruxism 
3. Impaired sleep pattern from early infancy 
4. Abnormal muscle tone followed by muscle wasting and dystonia
3
 
                                                 
1
 Brain disease [Nørgaard, 2001] 
2
 Impairment of the ability to perform coordinated movements [Merriam-webster, 2008] 
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5. Peripheral vasomotor disturbances 
6. Scoliosis
4
/kyphosis
5
 progressive through childhood 
7. Growth retardation 
8. Hypotrophic
6
 small and cold feet; small and thin hands 
 
Exclusion criteria 
1. Organomegaly
7
 or other signs of storage disease 
2. Retinopathy
8
, optic atrophy
9
, or cataract
10
 
3. Evidence of perinatal or postnatal brain damage  
4. Existence of identifiable metabolic or other progressive neurologic disorder 
5. Acquired neurologic disorders resulting from severe infarctions or head trauma                     
                                                                                       
 
 
 
Table 2 Revised Diagnostic Criteria for variant RTT [Jedele, 2007; Hagberg, 2002]                                                                                        
Revised delineation of variant phenotypes 
 
Inclusion Criteria 
1. Meet at least 3/6 main criteria 
2. Meet at least 5/11 supportive criteria  
 
Six main criteria 
1. Absence or reduction of hand skills 
2. Reduction or loss of babble speech 
3. Monotonous pattern to hand stereotypies 
4. Reduction or loss of communication skills 
5. Deceleration of head growth from first year of life 
6. RTT disease profile: regression stage followed by recovery of interaction contrasting with slow neuromotor   
    regression 
 
Eleven supportive criteria 
1. Breathing irregularities 
2. Bloating/air swallowing 
3. Harsh sounding bruxism 
4. Abnormal locomotion 
5. Scoliosis/kyphosis 
6. Lower limb amyotrophy
11
 
7. Cold, purplish feet, usually small 
8. Sleep disturbance, including night screaming 
9. Laughing/screaming spells 
10. Diminished pain response 
11. Intense eye contact/eye pointing 
                                                                                       
 
 
                                                                                                                                                                  
3
 A state of disordered tonicity of tissues (as of muscle) [Merriam-webster, 2008] or sustained muscle contractions 
cause twisting and repetitive movements or abnormal postures [National institute of health, 2008]. 
4
 The spine is curved from side to side [Merriam-webster, 2008].   
5
 Also called “hunch back” [Merriam-webster, 2008].   
6
  Progressive degeneration of an organ or tissue caused by loss of cells [Nørgaard 2001]. 
7
 Abnormal enlargement of organs [medilexicon, 2008].  
8
 Non-inflammatory damage to the retina [Merriam-webster, 2008].   
9
 Degeneration of the optic nerve [Merriam-webster, 2008].   
10
 A clouding of the lens of the eye [Merriam-webster, 2008].   
11
 Atrophy of a muscle [Merriam-webster, 2008].   
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1.1 Clinical presentation  
 
1.1.1 Classic RTT 
 
Classic RTT is noticed primarily in the infancy, and especially in the first 4 years of life. 
Development of infants occur normally until the age of 6-18 month [Shahbazian & Zoghbi, 2002; 
2001] after which the expression of the mutated MECP2 may affect the neurological development 
followed by an abrupt loss of motor skills and acquired language [Hagberg et al., 1983]. Some of 
the characteristic features of classic RTT include abnormal movements like stereotypic hand 
wringing, hand dyspraxia, decelerated head growth, hypotonia, mental retardation, postnatally 
microcephaly, abnormal breathing and ataxia
12
 [Shahbazian & Zoghbi, 2002, Renieri et al., 2003]. 
These characteristic abnormalities displayed in a RTT patient determine in which stage (see table 3) 
of the disease they are in. [Hagberg, 2002; Hagberg et al., 1983; Shahbazian & Zoghbi, 2002; 
Jedele, 2007] 
 
Stage 1 
Stage 1 takes place after the period of normal development, from 6-18 month of age, and during this 
stage the developmental progress ceases and hence new skills is delayed. After the first 6 months 
abnormal signs are observed in which especially the general motor performance is very impaired. 
This includes crawling, sitting, and later walking. Postural stiffness, tremor, and body stereotypies 
occurs [Jedele, 2007; Nomura & Segawa, 2005]. Within a few weeks to months there is seen a 
regression which displays in autistic behaviour such as emotional withdrawal and in decelerating 
head growth [Jedele, 2007; Hagberg & Witt-Engerström, 1986; Shahbazian & Zoghbi, 2002; 
Hagberg, 2002]. This stage may not seem completely abnormal compared with the following stage 
2 where the abnormal behaviour becomes more visible. 
 
                                                 
12
 Lack of coordination of movements [Nørgaard, 2001] 
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Stage 2 
This stage sets in at a age of 1-4 years and involves a developmental regression where motor skills 
are slowly lost. The characteristics are lack of useful hand movements followed by abnormal hand 
movements - hand wringing, loss of obtained skills such as speech and also loss of communication 
seen by diminished eye contact. In addition to these characteristics other abnormalities can be 
observed in RTT females, including tongue protrusion, bizarre smile and a burst of abnormal facial 
expression. Also asymmetric neuromuscular weakness, irregular breathing patterns, truncal and gait 
ataxia/ apraxia
13
 develops. The duration of this stage can be weeks to possibly a year [Hagberg, 
2002; Jedele, 2007; Hagberg & Witt-Engerström, 1986; Shahbazian & Zoghbi, 2002].    
 
Stage 3 
During stage 3 (age 2-10 years) the development appear to experience certain stabilization which 
shows in recovery of contact and communication; however, inability to speak, slow neuromotor 
regression, hand ataxia/apraxia is prominent and the stereotypic hand activities persist. This is a 
relative ‘silent’ period [Hagberg & Witt-Engerström, 1986]. The girls still develop other handicaps, 
such as severe scoliosis, reduced somatic growth, and epilepsy [Renieri et al., 2003; Hagberg & 
Witt-Engerström, 1986]. The duration of the stage is years to decades [Hagberg, 2002; Renieri et 
al., 2003].     
 
Stage 4 
The last determined stage in classic RTT takes place through school age and adolescence (age 5-15 
years and older). Motor deterioration continues and brings girls in a non-mobile position, which 
results in complete wheelchair dependency accompanied by hypoactivity, especially among those 
who cannot walk because of development of sclerosis [Shahbazian & Zoghbi, 2002; Hagberg, 2002; 
Hagberg & Witt-Engerström, 1986].  
Division of above-mentioned stages of RTT and their symptoms are presented in table 3. 
 
                                                 
13
 Loss or impairment of the ability to execute complex coordinated movements without muscular or sensory 
impairment [Merriam-webster, 2008]   
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Table 3 Clinical Stages and Manifestations of RTT [Jedele, 2007; Hagberg, 2002].                                                                                         
 
Stage Descriptor Age of Onset  Clinical Features                     Duration 
 
1 Early-onset Onset: 5 to 18 months  Delayed developmental progress                    Weeks to  
Stagnation Druration: Month Poor postural control                      months 
“Bottom shufflers” 
 
2  Developmental Onset: 1 to 4 years Loss of acquired skills, including fine motor, Weeks to 
Regression Duration: Weeks to month babbling or words, and active playing             months 
Intermittently “in another world” 
Cognitive impairment apparent 
Still using eye contact 
Mild breathing abnormalities 
Seizures in only 15% 
 
3  Pseudostationary Early childhood   Some communication improvements               Years to 
Phase     Onset: 2-10 years “Wake-up” period                       decades 
   Duration: Months to years Preserved ambulation (a few are never 
  ambulant) 
Marked hand apraxia/dyspraxia 
Slow neuromotor regression 
Seizures most frequent and severe 
 
4  Late motor loss of ambulation or Severe wasting and debilitation leading to       Decades 
deterioration severe debilitation “frozen stiffness” 
in patients who never  Complete wheelchair dependency 
walked  Seizures may lessen or disappear 
                          Onset: 10+ years         
  Druration: Years                     
 
1.1.2 Variant RTT 
 
There are different variations of RTT, which are expressed in milder and more severe degrees than 
classic RTT. These atypical forms of RTT deviates from the classic RTT pattern in age of onset, 
sequences of clinical profile, severity/presence of expected signs or in all of these areas and this 
creates diagnostic difficulties [Hagberg et al., 2002]. It can result from a skewed X-chromosome 
inactivation (see “2.4 Phenotype and Genotype Correlation”), which can lead to both a milder and 
a more severe degree of RTT. The more severe variant RTT appears early in the course of the 
disease, with early onset of regression and seizures and lack of normal development stage. It 
includes symptoms like infantile hypotonia without any developmental progress and autisme. 
Milder variant RTT display mild neurologic symptoms and others shows regression gradually with 
good gross motor, speech and hand skills, and a symptom free mutation carrier phenotype [Jedele, 
2007; Amir & Zoghbi, 2000; Hagberg, 2002].        
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Common for both classic and variant RTT is the evident characteristic of the abnormal hand 
movements. Stereotypical hand movements already develop in infancy (stage 1), and become more 
and more obvious through stage 2 and especially in stage 3, where it develops to a combination of 
hand-washing and wringing movements. In addition social withdrawal, communication 
dysfunction, loss of acquired speech, and cognitive impairment are hallmarks of RTT [Jedele, 2007]  
 
Distinct clinical features detected in early behaviours of the RTT child makes it possible to give an 
early diagnose and let the infant be tested for MECP2 mutations. This also makes a possibility to 
determine phenotype-genotype correlations for the various MECP2 mutations.   
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2 MeCP2 Gene and Function 
 
2.1 MeCP2 Gene and Product 
 
 
MECP2 is an X-linked gene, which encodes for the Methyl-CpG binding protein 2, MeCP2 
[Esposito et al., 1996]. The gene is composed of four exons that undergo alternative splicing and 
can yield two isoforms of the protein; MeCP2A and MeCP2B which differ in the presence or 
absence of exon 2 and 1 (see figure 1) [Kriaucionis & Bird, 2004]. MECP2 is a housekeeping gene 
and most human tissues express both forms with a higher proportion of MeCP2A except for the 
brain where MeCP2B is predominant [Ham et al., 2005]. It is noticeable that, even though MECP2 
is a housekeeping gene, mutations only seem to affect the brain tissue in RTT. Supporting this 
observation, mice with brain-specific deletion of MECP2 show a phenotype identical to MECP2-
null mice (See “4.2 RTT mouse models”) [Chen et al., 2001]. MeCP2 is highly expressed in the 
postnatal brain indicating that it may have a central role in the postnatal development of the central 
nervous system (CNS), which correlates with the onset and characteristic symptoms of RTT [Guy et 
al., 2001].  
MeCP2 has two distinct domains, conserved in both isoforms, which are important for its functions 
the 85-amino acid Methyl-CpG Binding Domain (MBD) [Nan et al., 1993] and the 104-amino acid 
Transcription Repression Domain (TRD) (see figure 1) [Nan et al., 1997]. MeCP2 binds to 
methylated DNA at symmetrical pairs of methyl-CpG dinucleotides through its MBD [Nan et al., 
1993]. Then, through its TRD, it associates with the Sin 3A corepressor complex that contains 
histone deacetylase 1 and 2 (HDAC1 and HDAC2), which then modify the chromatin structure and 
thereby initiate transcriptional repression [Nan et al., 1998; Jones et al., 1998]. However MeCP2 
also seems to repress transcription in an HDAC-independent manner since its repression in not fully 
alleviated by the histone-deacetylase inhibitor, trichostatin A (TSA) [Yu et al., 2000]. Within TRD 
lies the localization signal sequence (NLS) which facilitates transport of the protein into the nucleus 
[Huppke et al., 2002].  
MeCP2 is a member of at family of proteins with the MBD in common. The family includes; 
MeCP2 and MBD1-4. All, except MBD3, can bind to methylated DNA and in addition MeCP2, 
MBD1 and MBD2 can repress transcription [GeneCards, 2008] and the MBD1 and -2 has been 
shown to be expressed in somatic tissues [abcam, 2008].   
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Figure 1: A) Shows the two isoforms of MeCP2 (MeCP2A and MeCP2B) with the MBD and TRD. The numbers 
refer to the exons and the white regions are non-coding sequences. CTR stands for carboxy-terminal region. B) 
Shows a diagram of MECP2’s genomic structure [Francke, 2006]. 
 
 
2.2 The Mechanism of MeCP2 Repression 
 
The function of MeCP2 is strongly coupled to DNA methylation, and an understanding of the role 
of methylation is necessary to gain insight into the molecular basis of RTT.  
 
DNA methylation is a chemical modification of the DNA and probably 1 percent of DNA bases are 
modified postsynthetically. This mechanism is catalyzed by one of the three DNA 
methyltransferases (DNMTs) DNMT1, 3a, and 3b [Robertson, 2002]. DNA methylation involves 
additions of methyl groups typically at the carbon-5 position of the cytosine ring within 
cytosine/guanine (CpG) islands of the DNA. Letter “p” signifies the phosphodiester bond that 
connects cytosine and guanine. These islands vary in length from 200 bp to 2 kbp. The CpG islands 
are commonly unmethylated, and are used as a regulatory mechanism for some genes. In addition 
the CpG islands are located in the promoter regions, which supports that CpG islands are important 
for the regulation of genes. Methylation of CpG islands has the effect of reducing the gene 
expression; this means that in transcriptionally active regions the chromatin has unmethylated DNA 
whereas inactive regions contain methylated DNA. [Tang & Ho, 2007] 
Two mechanisms have been proposed to explain the inhibitory effect of CpG island methylation on 
gene transcription. The first mechanism suggests that when CpG islands are methylated, the 
additional methyl group on the carbon-5 position extends into the major groove of the DNA, 
thereby inhibiting the binding of TFs to their recognition sites. This suppresses the gene 
transcription. The second mechanism involves MeCP2, which has a high affinity for methylated 
CpG islands. When the protein binds to methylated CpG islands, it creates a steric hindrance that 
inhibits the access of TFs [Tang & Ho, 2007]. The MeCP2 partly recruits histone deacetylases and 
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histone methyltransferases before binding to methylated CpG islands. The detailed mechanism for 
acetylation and deacetylation of histones includes histone acetyltransferases (HATs) and histone 
deacetylases (HDACs).  The function of HAT is to acetylate nucleosomal histones for activation of 
the chromatin for transcription in particularly lysine residues in the amino-terminal of histones H3 
and H4. The acetylation of multiple lysine residues is associated with gene transcription because 
acetylation of H3 and H4 reduces the affinity of histones for DNA. This allows a relaxation of the 
chromatin and activation of gene transcription. Reversely in transcriptional silencing, the histones 
are deacetylated by HDACs, meaning that the DNA histone affinity is no longer reduced and the 
chromatin is in a transcriptionally inactive state [Nelson & Cox, 2005].  That is why DNA 
methylation is working together with histone modifications to affect the chromatin packaging, so 
the regions of chromatin with high levels of acetylated histones and DNA that is unmethylated, is 
an active region for gene transcription, whereas chromatin regions with deacetylated histones and 
with methylated DNA is inactive for transcription (see figure 2) [Rodenhiser & Mann, 2006].  
 
 
Figure 2: This illustration shows the how DNA methylation and histone modification work hand in hand and 
reversibly to regulate the chromatin structure and thereby gene expression [Rodenhiser & Mann, 2006].  
 
2.3 Mutations in MeCP2 
 
MECP2 mutations have been identified in about 70-90% of patients with classic RTT [reviewed in 
Shahbazian et al., 2002B]. The clinical phenotype of RTT patients varies greatly from mild forms 
with preserved speech to more severe variants [Zappella et al., 2002]. This disparity has been 
studied in connection with the genotype of RTT patients to investigate if there is a correlation 
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between the type and location of mutations in the MECP2 gene and the resulting phenotype. For 
this purpose it is necessary to divide patients into categories based on the extent of their phenotype 
and distinguish between different types of mutations.  
 
To evaluate the clinical severity of the syndrome for the patients in question, different features must 
be assessed such as feeding problems, muscular tone, locomotor ability, seizers and scoliosis, and 
must be given a score depending on severity [Hoffbuhr et al., 2002]. To estimate the level of 
typicality it is helpful to know the onset of regression, acquired speech and use of hands. However, 
the scoring system of different phenotype/genotype correlation studies varies and this makes it 
difficult to make cross studies. In addition, the full presentation of RTT emerges with age and 
therefore comparisons can not be made between patient under and above 15 years of age, which 
further complicates such studies [Charman et al., 2005]. 
   
To date more than 216 different mutations have been recognized in MECP2. A number of non-RTT 
neurological and/or psychiatric symptoms can result from mutations in MECP2. These result in 
Rett-like symptoms such as impaired gross and fine motor skills and they often affect boys [Ham et 
al., 2005]. However the majority of children with MECP2 mutations develop RTT. Mutations can 
be divided into missense mutations, frameshift mutations and late and early truncating mutations. 
Like nonsense mutations, frameshift mutations are likely to result in premature truncation, which 
causes the MeCP2 protein to lose its ability to repress transcription [Amir & Zoghbi, 2000]. In 
general mutations that truncate upstream of NLS is regarded as early truncating mutations. 
Mutations that truncate within or downstream of NLS are regarded as late truncating. It is very 
important for the function of MeCP2 because without it, the protein would most likely be excluded 
from the nucleus and thereby be unable to bind to methylated DNA and repress transcription 
[Huppke et al., 2002] 
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2.3.1 Common mutations in RTT 
 
Point mutations 
Eight to nine different point mutations account for the majority of the cases of RTT and these are 
typical de novo mutations that occur in the paternal sperm cells. The mutation happens because of a 
deamination of a methylated cytosine residue during hypomethylation of the male pronucleus after 
fertilization [Mayer et al., 2000]. This leads to a cytosine to thymine alteration and the mistake is 
not corrected by repair mechanisms for some reason. De novo mutations can also explain the 
sporadic cases of RTT where no parental phenotypes are to be found [Wan et al., 1999].  
 
Patients with atypical RTT, showing either early onset of regression and seizures or a milder 
incomplete form, are less likely to have a mutation in MECP2. This suggests that other genes could 
be involved; Mutations in the gene Cyclin-Dependent Kinase-Like 5 (CDKL5) has shown to cause a 
phenotype resembling that of RTT. When MECP2 mutations are found in mild variants of atypical 
RTT the most frequent type is carboxy-terminal truncations which allow for residual function 
because it does not affect BMD or TRD. This type of mutation, however, is also found in classic 
RTT cases [Ham et al., 2005]. 
 
Missense- and truncating mutations 
In independent cases, 216 pathogenic mutations had been reported in the year 2000 displaying 64 
different mutations of which 23 are missense mutations and 41 are truncating mutations. [reviewed 
in Amir & Zoghbi, 2000]. No mutations have been detected in exon 2 (from MECP2A). Most of the 
mutations in MECP2 are located in the MBD and TRD of the protein or result in frameshift and/or 
premature truncation of the protein. Missense mutations are primarily located in the MBD and the 
TRD commonly carries nonsense- and deletion mutations [Yusufzai & Wolffe, 2000]. In vitro 
studies show that missense mutations in MBD and nonsense mutations in TRD most likely result in 
loss of function of the protein by affecting the ability to bind methylated DNA or to associate with 
transcription co-repressors [Ballerstar et al., 2000] (see “2.2 The Mechanims of MeCP2 
Repression”).  
The figures below show the frequency of missense and nonsense mutations. 
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Missense mutations can be divided into three groups: 1) Mutations that occur in residues on the 
DNA-binding surface. 2) Mutations that occur in residues that make up the core of the domain, 
which leads to a decrease in stability of the domain and thereby loss of DNA-binding. 3) Mutations 
in amino acids that have small effect on the stability and binding of MBD [reviewed in Jørgensen & 
Bird, 2002]. As mentioned before nonsense mutations in TRD can have great consequence on the 
residual function of MeCP2 especially if it affects NLS and thereby the entering into the nucleus.  
   
2.4 Phenotype and genotype correlation  
 
Several studies have analyzed RTT patients for their molecular lesion and resulting phenotype but 
there have been some inconsistencies in their conclusions to whether a correlation is seen. Despite 
of this, an overall picture has appeared; missense mutations seem to be associated with a less severe 
phenotype than truncating mutations and early truncating mutations are associated with the most 
severe outcome [Charman et al., 2005]. The consequence of a missense mutation must relay a great 
deal on where in the gene it is found, but present studies is not in agreement on whether it has the 
worse outcome if it is located in the MBD or in the TRD [Ham et al., 2005]. Amir & Zoghbi [2000] 
Figur 3: Frequency of missense mutations. The 
majority of missense mutations are located in BMD 
domain [International Rett Syndrome Foundation, 
2008].                     
Figur 4: Frequency of nonsense mutations. The 
majority of nonsense mutations are located in TRD 
domain [International Rett Syndrome Foundation, 
2008].  
 17 MeCP2 and Rett Syndrome – The role of MeCP2 in brain dysfunction of Rett Syndrome 
investigated the correlation of mutation type and presentation of specific symptoms of RTT. A 
positive correlation was found between truncating mutations and breathing abnormalities plus 
missense mutations and scoliosis. However it did not find any correlation between severity of the 
disease and type of mutation. Other parameters tested were age of onset, death, seizures and somatic 
growth impairment, which came out with no association. However there has been no consistency in 
the results of these kinds of investigations. 
 
It has therefore been determined that there is no direct and simple correlation between phenotype 
and genotype as individuals with identical mutations can exhibit completely different phenotypes. 
This can perhaps partly be explained by skewed X-chromosome inactivation, which can result in a 
surprisingly mild or severe outcome of RTT according to the distribution of active X-chromosomes 
[Charman et al., 2005]. It is the accepted perception that the silencing happens more or less at 
random and girls normally display an equal amount of each chromosome inactivated. Around 91% 
of patients with documented MECP2 mutations have random X-chromosome inactivation in their 
peripheral blood leukocyte DNA [Amir et al., 2000]. However, the pattern of X-chromosome 
inactivation in the brain may differ, but this is hard to test as it is not possible to collect samples 
from brain tissue from live human subjects [Ham et al., 2005] and in some cases skewed X-
chromosome inactivation has been shown to prevent RTT from penetrating [Hoffbuhr et al., 2002]. 
One of the sisters from a monozygotic twin pair has been reported to be asymptomatic while the 
other sister was diagnosed with RTT. They both had a frameshift mutation in MECP2 but displayed 
different X-chromosome inactivation in leukocytes. The girl with RTT had a random pattern of 
inactivation (40:60) while the other sister showed a particularly skewed pattern (99:1) which most 
likely protected her against the syndrome if the inactivation profile was similar in the brain 
[Hoffburh et al., 2001]. Furthermore genetic background can play a role in the different phenotypic 
outcomes of individuals with the same MECP2 mutation. This is supported by the fact that Mecp2-
null mice experience varying body weight with extreme weight loss dependent on their genetic 
background. RTT patients with a variant of RTT called preserved speech are often overweight 
[Zappella et al., 2001]. This indicates that one or more modifier genes exist and mediate effects of 
MeCP2 on body weight [Guy et al., 2001].                
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2.5 Target genes of MeCP2 
 
MeCP2 has been thought to be a global regulator of transcription. Therefore many studies have tried 
to identify MeCP2 target genes by making global gene expression analysis of brain tissues from 
RTT mice and Mecp2-null mice. However none of these studies have succeeded in presenting 
results showing major changes in gene expression in RTT- or Mecp2-null mice brains, and the small 
changes found do not seem to overlap [reviewed in Francke, 2006]. This indicates that MeCP2 does 
not function as a global transcriptional regulator as previously thought, but alternatively may lead to 
subtle gene expression changes [Tudor et al., 2002]. This also explains the results of the global 
analysis, in the way that if MeCP2 in fact controls the degree of expression in a specific number of 
genes in different subsets of neurons, this change of expression would not be detected in a brain 
tissue sample, which contains a lot of vastly different neuronal cell types [reviewed in Francke, 
2006].  
Recent studies have therefore used candidate gene approaches instead of global expression samples 
to identify target genes of MeCP2. A variety of gene candidates have been proposed and some have 
been studied more extensively than others. Those best studied are showed in table 4.  
 
Table 4 An overview of the most studied MeCP2 target gene candidates [Chahrour & Zoghbi, 2007]. 
 
 
Despite all these studies, only one gene has been identified as a reliable MeCP2 target gene 
[Chadwick & Wade, 2007]. This gene, brain-derived neurotrophic factor (BDNF), plays an 
important role in the survival [Bonni et al., 1999], differentiation [Ghosh et al., 1994] and plasticity 
Gene Function 
BDNF 
Neuronal development  
and survival 
xHairy2a Neuronal repressor 
DLX5 
Neuronal transcription  
Factor 
Sgk1 Hormone signaling 
Fkbp5 Hormone signaling 
Uqcrc1 
Mitochondrial  
respiratory chain 
ID1-3 
Neuronal transcription 
Factors 
FXYD1 Ion channel regulator 
IGFBP3 Hormone signaling 
Chr Neuropeptide 
UBE3A  Ubiquitin ligase 
GABRB3 GABA-A receptor 
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[Poo, 2001] of neurons. bdnf also has an important impact on serotonergic (5HT) neurons, which 
are important for locomotion.  This was shown in Mamounas et al., [1995] where rats were exposed 
to a neurotoxin, which causes loss of serotonergic axons. This severe neurotoxin-induced loss of 5-
HT axons, were completely prevented by infusion of bdnf. Also infusions of bdnf caused an 
increase of 5-HT axon density [Mamounas et al., 1995]. Furthermore bdnf has been shown to have 
an effect on dopamine (DA) secreting neurons, which are important for control of several brain 
functions including voluntary movement. Dopamine and serototonine have been shown to function 
as Maintenance Growth Factors (MGF), which are required in order to maintain a mature phenotype 
[reviewed in Azmita, 2001]. 
Four promoters control rat- and mouse bdnf, of which promoter III in rat and promoter IV in mouse 
are sensitive to calcium influx through voltage-sensitive calcium channels [Tao et al., 1998].  Chen 
et al., [2003] discovered that Mecp2 binds to promoter III of bdnf in wild type cultured cortical 
neurons obtained from rats, and that this binding depends on the activity of the neuron. Mecp2 only 
binds to the bdnf gene in non-active neurons, which then leads to repression of the gene (see figure 
5A). In active neurons Chen et al., [2003] showed, that depolarization of the membrane, caused by 
exposure to potassium chloride (KCl), triggers calcium influx and phosphorylation of Mecp2 at 
serine 421. This phosphorylation causes Mecp2 to disassociate from promoter III. But before 
allowing fully transcription of bdnf, three transcriptional activators: Calcium-Response Factor 
(CaRF), Upstream Stimulatory Factors (USF), and Calcium Responsive Element Binding protein, 
(CREB), must be present (see figure 5C).  In deficiency of Mecp2, the bdnf repression in resting 
neurons becomes less efficient, which results in a 2 fold increase of bdnf mRNA levels (see figure 
5B) [Chen et al., 2003]. To further support this Martinowich et al., [2003] showed that increased 
expression of bdnf in mouse cortical cultures triggered by depolarization, correlated with decreased 
methylation of CpG in promoter IV of the bdnf gene. This study also shows that an increased 
transcription of bdnf is associated with release of Mecp2 and its associated co-repressor complexes 
from promoter IV of the mouse bdnf [Martinowich et al., 2003]. 
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Figure 5: This illustrates the bdnf transcription in the absence and presence of Meecp2 in active and inactive 
neurons. (A) In the presence of Mecp2 in the inactive neuron, Mecp2 (red) associates with its co-repressor (here 
designated HDAC in green). This complex binds to the bdnf promoter, and blocks upstream stimulatory factors, 
USFs, thus repressing transcription. (B) In the absence of Mecp2, the repression of the gene becomes less 
efficient, and result in low-level transcription. (C) When the neuron depolarize, it triggers calcium influx and 
phosphorylation of Mecp2 at serine 421, are triggered. This causes Mecp2 to disassociate from the promoter. But 
before allowing full transcription of bdnf, three transcriptional activators: CaRF, USF and CREB, must be 
present. [Callabro & Hendrich, 2005 edited by Andersen]. 
 
The discovery that Mecp2 deficiency leads to a 2 fold increase in bdnf-levels, were based on in 
vitro assays. In vivo studies performed by Chang et al., [2006] supported the hypotheses of bdnf 
being a Mecp2 target gene, but their result showed a 30 % decrease of bdnf in whole brain lysates 
from 6-8 week-old Mecp2 mutant mice. Furthermore it was discovered that the RTT-like 
phenotypes associated with the mutant Mecp2 were more severe in the absence of bdnf and 
improved by 2 fold increase in bdnf-levels, which indicate that BDNF is needed for normal 
 21 MeCP2 and Rett Syndrome – The role of MeCP2 in brain dysfunction of Rett Syndrome 
development, and that a lowered level contributes to development of RTT-like symptoms [Chang et 
al., 2006]. These findings conflict with the in vitro studies, and with the idea of MeCP2 as a 
repressor. It is clear that BDNF is a target gene of MeCP2 and that it contributes to the RTT 
symptoms caused by deficiency of MeCP2, but it is not clear whether MeCP2 works as a repressor 
or an activator regarding BDNF. These conflicting results could be explained by earlier in vivo 
findings which show a decreased cortical activity in Mecp2 mutant brain [Dani et al., 2005]. The in 
vitro study by Chen et al., [2003], is made under the assumption that the neuronal activity is the 
same in wild type and Mecp2 mutant brains. Taking this into account, the discrepancy between the 
in vitro and the in vivo study could be a result of different levels of neuronal activity in the wild 
type brain and Mecp2 mutant brain. The decrease in bdnf expression level obtained from the in vivo 
study could thus be due to an overall decreased neuronal activity and thereby decreased initiation of 
transcription. [Chang et al., 2006]. This explanation supports the concept of MeCP2 being a 
repressor.  Chahrour et al., [2008] explains the results showing an in vivo decreased bdnf level, by 
demonstrating that Mecp2 acts both as an activator and a repressor of transcription, and further 
suggests that Mecp2 might initiate transcription in the case of bdnf. Chahrour et al., [2008] 
examined the expression patterns in hypothalamus of Mecp2-null mouse and mouse over expressing 
Mecp2. To support their results showing that Mecp2 is an activator, they further showed that Mecp2 
binds to the promoter of six selected genes, and that it associates with the transcriptional activator 
CREB1 at the promoter of activated target genes but not in repressed target genes [Chahrour et al., 
2008].  These findings indicate that MeCP2 does not only work as a repressor, but also seems to 
initiate transcription in a great number of genes. Despite the function of MeCP2 as either a 
repressor or an activator, it seems to change transcription patterns of genes located in brain tissue 
that primarily are involved in neurodevelopment or -function. 
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3 Human Brain Development 
 
It is important to obtain an understanding of the normal neurodevelopmental processes to identify 
when and where, during brain development, deficiency of MeCP2 could affect brain maturation and 
function.   
 
During the prenatal period, almost all neurons of CNS finish proliferating however maturation of 
the brain continues until the age of 20. Prenatally the dendritic branching and the number of 
synaptic connections increase excessively. These processes reach a peak, which time point and 
degree varies depending on the type of neurons and areas of the brain. The peak is later followed by 
dendritic pruning and synapse elimination to remove the unnecessary synapses and thereby 
attaining a set of connections that are more efficient. This is a lifelong process and synaptic 
connections are continuously remodeled and vary greatly in different brain regions [Nowakowski & 
Hayes, 2002; Chungani, 1998].  
The cortex and subcortical gray matter nuclei develop during the fetal period by a sequence of cell 
proliferation, migration and maturation (see figure 6). The process of proliferation happens in the 
germinal layer of the cerebral cortex also called the ventricular zone (VZ), this means that the 
neurons must move from the site of their proliferation to their final destination. Initially the VZ 
contains progenitor cells, which proliferate into glial and neuronal cells [Noktor et al., 2001; Brown 
et al., 2000]. The glial fibers, which are produced first, are radially oriented. It means that they are 
spanning the cortex from the VZ to the outer pial surface, and thereby provides the scaffolding for 
the later migration of neurons. Then these neurons migrate from the VZ to the pial surface where 
they accumulate below the marginal zone to form pyramidal or cortical plate (CP) through the 
intermediate zone. The so-called inside-out structure of the mature cerebral cortex is layered during 
the development. The following migrating neurons form the preplate, which is a transient layer that 
divides into the subplate (the plate below) and the superficial marginal zone. This is additionally 
forming a layer in between called the cortical plate. These cells become layers five and six - the 
deep layers of the mature cortex. Neurons that are later produced, migrate past the deep layer 
neurons (older neurons) and thereby forming the upper cortical layers [Brown et al., 2000; Marin-
Padilla, 1998].  
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Figure 6: The illustration shows the cell migration during the development of the cerebral cortex and how the 
neurons become layered in the inside-out structure [Brown et al., 2001]. 
 
During neuronal differentiation, neurons develop their axon and dendrite by growing exuberantly 
and making an excess of synapses. This means that axon grow to an area that is broader than its 
distribution and makes transient connections during maturation. But in order to establish the 
efficient pattern of connection, these connections are eliminated either by cell death or cellular 
pruning. While the neurons are differentiating by gaining mature properties, the glial cells are also 
differentiating into oligodendrocytes that make myelin and astrocytes. During differentiation of the 
neurons, they express specific enzymes later used to produce neurotransmitters 
[Brown et al., 2001].  
 
Chungani et al. [1987] has measured the levels of local cerebral metabolic rates for glucose in 
different human brain regions from newborn to adolescense with positron emission tomography 
(PET). Glucose levels reflect functional activity in the measured area. Thereby the glucose 
utilization increases during different developmental stages that are related to behavioral maturation, 
synaptogenesis, plasticity, and other neuro-maturational. The results of the PET showed that the 
human brain undergoes a postnatally period of maturation that is much more protracted than 
prenatally. Chungani et al. [1987] showed that human brain maturation proceed at least into the 
second decade of life and the ontogeny of glucose metabolism follows a developmental order, with 
functional maturation of older anatomic structures preceding that of newer regions, which indicated 
that older cortical areas mature earlier than the newer areas. 
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4 Correlations between RTT, MeCP2 and Brain Development 
 
4.1 The Neuropathology of RTT  
 
Studies of MeCP2 expression during human development have revealed that the protein is 
expressed primarily in neurons at the time they become fully matured [Shahbazian et al., 2002B]. It 
is interesting whether the progression of RTT can be linked directly to the deficiency of MeCP2. To 
investigate this, it is necessary to consider the abnormalities of RTT brains and, if possible, further 
link these abnormalities to the target genes of MeCP2 and ultimately the symptoms of RTT. 
 
4.1.1 The brains of RTT patients are reduced in size         
 
As mentioned, RTT is a progressive disorder and is also called a brain disease because of the fact 
that magnetic resonance imaging (MRI) and autopsy examinations reveal that the brain of RTT 
patients are smaller than normal and the only organ visibly affected [Schahram, 2003]. The brain 
size is decreased with 12-34 % compared with controls of the same age [Jellinger et al., 1988]. 
Furthermore the cerebrum appears to be more affected than the cerebellum [Subramaniam et al., 
1997]. The RTT brain does not become progressively smaller over time, but there is seen a 
decreasing rate of brain growth which starts when a RTT child is about 3-4 months old. MeCP2 is 
not thought to be involved in brain development at the earliest stage. This is concluded because 
neurons of the VZ, which are responsible for neural stem cell proliferation, normally do not express 
the protein during fetal development [Shahbazian et al., 2002B; Armstrong, 2005]. The stable brain 
size and the absence of markers for degenerative changes observed by MRI, support the theory of 
the decreased brain size in RTT being a result of stunted brain development and not degeneration of 
the brain and the number of neurons appears relatively preserved [Armstrong, 2000; Armstrong, 
2005]. It is noteworthy that the morphology of brains from RTT-patients appears surprisingly 
normal, and that the changes have been difficult to distinguish [Armstrong, 2004].    
 
Subramaniam et al. [1997] investigated brains of RTT patients by MRI studies and found that, the 
reduction in brain size is distributed throughout the brain and affects both the white and especially 
the grey matter in different regions. The reduction is mainly seen in the prefrontal, posterior frontal, 
and anterior temporal regions, but the size of the cerebellum is not affected, as opposed to other 
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studies (see figure 7) [Subramaniam et al., 1997]. The dendritic branching is reduced in the 
pyramidal neurons in the frontal-, motor- and inferior temporal regions (see figure 7), which is 
partly thought to explain the reduced brain size. The decreased dendritic branching in RTT suggests 
that the synaptic input also is reduced [Armstrong, 2000; Armstrong, 2005]. In addition the 
neuronal cell packing density has been reported to be decreased which supports the failure to 
develop dentritic connections between the neurons [Bauman et al., 1995]. The expression of 
MeCP2, which increases after birth until adolescence, possibly reflects maturation of neurons, 
synaptogenesis and development of dendritic branching [Armstrong et al., 2003]. Kauffman [1995] 
reported reduction of Microtubule-Associated Protein 2 (Map2) in the motor and frontal cortex of 
RTT brains. During development, interactions between Map2 and tubulin are important for 
extension of neuronal growth cones
14
 and dendritic growth. That makes Map2 an important marker 
of neurons having obtained mature properties and thus it seems likely that mutations in MeCP2 are 
involved in the reduction of dendritic branching. However it is still unclear if reduced Map2 is 
directly related to MECP2 mutations [Armstrong, 2004].     
 
Figure 7: Shows the different brain regions [Widmaier et al., 2008]. 
                                                 
14
 A growth cone is a dynamic, actin-supported extension of a developing axon seeking its synaptic target [Dent et al., 
2003] 
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4.1.2 Elevations of excitatory brain signals in the frontal cortex can explain RTT 
symptoms   
 
The constant stereotypic hand movements, breathing abnormalities and the occurrence of seizures 
displayed in RTT indicate that excitatory synaptic activity may be affected [Yamanouchi et al., 
1993]. Johnston et al. [2001] focused on the disruption of synaptic development with the theory that 
the defects in RTT patients is caused by the failure of mutant MeCP2 to promote gene silencing. 
They investigated the density of four subtypes of receptors for the excitatory neurotransmitter, 
glutamate, in frontal cortex of RTT patients post mortem.  
 
An elevation of all four types in younger RTT girls (< 8 years) and a decrease in the older girls 
were seen - especially the N-methyl-D-aspartat (NMDA) (see figure 8). Normally NMDA densities 
remain high the first months of postnatal life and then decrease. Thus the higher levels in the young 
RTT continuing to the age of 8 years can be interpreted as persistence of the immature state 
[Johnston et al., 2001]. Synapses that use the excitatory amino acid neurotransmitter glutamate play 
an important role in circuits in the cerebral cortex, basal ganglia and brainstem, responsible for 
movement and breathing (See Appentix II). Thus increased number of glutamate receptors 
correlates with the hyperkinetic hand-wringing and breathing abnormalities that are seen in RTT 
patients which can be caused by the heightened excitatory neuronal activity. The hypothesis that 
hand-wringing is caused by increase in excitatory stimulation is supported by two studies where 
cerebrospinal fluid was examined. Elevated levels of glutamate were found, meaning that the 
synaptic levels of glutamate may be elevated [Hamberger et al., 1992; Lappalainen & Riikonen, 
1996].  
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Figure 8: Shows a comparison of NMDA receptor density, a subtype of glutamate receptors, in RTT- and control 
brains. An increase was seen in RTT brains until 8 years. Thereafter a decrease to subnormal levels occurs. 
[Johnston et al., 2001] 
 
4.1.3 Disruption of synapse development results in symptoms of Rett Syndrome 
 
Johnston et al., [2001] analysed gene expression in RTT brain and controls and found that a number 
of genes related to synapse function were consistently down regulated. This is in accordance with 
disruption of synapse development being a component of RTT pathology [Johnston et al., 2001]. 
Even though the down regulation of these genes seems inconsistent with the known role of MeCP2 
as a repressor, this can be explained by mutant MeCP2 failing to repress other repressor genes. 
These repressor genes could have the purpose of inhibiting transcription of the genes involved in 
synaptic function. This secondary inhibition would then incorrectly continue in persons with non-
functional MeCP2 [Johnston et al., 2001].  
 
The clinical data of RTT progression indicate that, during fetal life, development occurs close to 
normal (see “1 Rett Syndrome”). The emerging of symptoms such as deceleration of head growth 
and delaying of motor skills and speech around one year of age (see “1 Rett Syndrome”) coincides 
with increase of glucose metabolism and thereby synapse proliferation in the cerebral cortex of 
humans. [Chugani, 1998] The fact that synapse development is inhibited in RTT brains may reflect 
that mutant MeCP2 leaves the repressor genes “on” to repress genes which should be activated 
postnatally. Normally the pruning of excessive synapses happens around year 10 when also the 
decrease of glutamate receptors in RTT patients is seen. This coincides with the time of stabilization 
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of phenotype including seizures, which is seen in stage 4 in RTT (See “1 Rett Syndrome”). 
[Johnston et al., 2001].     
 
4.1.4 Damage on neurons in the brainstem results in the initial symptoms of Rett 
Syndrome 
 
It has been attempted to distinguish between primary, meaning initial, and secondary symptoms, to 
reveal the pathogenic lesion of RTT, when analyzing the different stages and symptoms of RTT. 
The basis for this is that the initial symptom is thought to directly reflect the defect neuron or 
neuronal system as the primary lesion. Segawa [2001] discussed this in the light of an earlier study 
of symptoms of 38 RTT patients [Segawa et al., 1998]. They assessed the age of RTT children 
reaching motor milestones such as head control, rolling over, sitting, crawling and walking. Every 
area was delayed in RTT children and 11 out of 20 began to walk before they began to crawl. This 
indicated that the impaired motor skills are not a sign of muscle weakness or a simple delay of 
motor skills but a disruption of certain neuronal systems [Segawa, 2001]. Stereotypic hand 
movements began from the age of 1 year and after these movements began, the children who had 
acquired some language lost this ability. Purposeful use of hands was seen in late infancy and early 
childhood before the stereotypic hand movements began.  
The primary disturbance appears to disrupt crawling and walking and later induces the loss of hand 
use and generates stereotypic movements. Furthermore the problems in crawling were more 
significant than in walking, which indicates failure of interlimb
15
 coordination not apraxia [Segawa, 
2001]. Locomotion is executed by the propriospinal
16
 circuit which is provoked by innervation of 
the brainstem noradrenergic (NA) and serotonergic (5HT) neurons. With the lack of tonic 
innervation, the locomotion is not provoked. Abnormalities in NA and/or 5HT neurons in the 
brainstem of RTT patients could be the cause of disrupted locomotion, which again could be caused 
by lesions in the early development of CNS. These neurons also regulate the posture [Mori et al., 
1992], which correlates with the hypotonia displayed in RTT patients (see “1 Rett Syndrome”).  
The stereotypic hand motions involve fixed posture of both hands after disappearance of purposeful 
hand use. This could be caused by dysfunction of dopamine- (DA) secreting neurons, which play a 
                                                 
15
 Rhythmic movements involving coordination between two limbs [Pang & Yang, 2001] 
16
 Relating especially or wholly to the spinal cord; specifically, denoting those nerve cells and their fibres that connect 
the different segments of the spinal cord with each other [CancerWEB, 2008] 
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central role in the control of several brain functions including voluntary movement. When analyzing 
the clinical progression of RTT the dysfunction of NA and 5HT neurons causing failure of 
locomotion appears to be the primary lesion. These aminergic
17
 neurons of the brainstem are known 
to be important in early postnatal brain development and early reduction of NA neurons in rats 
cause deceleration of brain growth [Brenner et al., 1983]. The aminergic neurons of the brainstem 
modulates the function of DA neurons through pedunculopontine nuclei (PPN). PPN is the main 
component of the reticular activating system located in the brainstem and thought to be involved in
 
the initiation and modulation of gait and other stereotyped
 
movements. This could create the 
secondary symptoms of stereotypic hand movements and loss of purposeful hand use. [Segawa, 
2001]. 
               
4.1.5 Important component of brain organization is reduced in RTT patients 
 
The size of cortical minicolumns is reduced in RTT patients [Casanova et al., 2003] as well as in 
autistic patients [Buxhoeveden et al., 2006]. A cortical minicolumn is a vertical column through the 
brain composed of around 80-100 interneurons and pyramidal neurons, and it is an important 
component of brain organization [Buxhoeveden & Casanova, 2002]. Cortical expansion is achieved 
by increased number of cortical minicolumns [Vernon, 1997]. The formation of columns requires 
C-R- and subplate neurons
18
 (see “3 Human Brain Development”) [Armstrong, 2004]. C-R neurons 
are normally some of the first neurons to express MeCP2 [Shahbazian et al., 2002B] and it is 
conceivable that lack of MeCP2 in these cells disrupt normal function of cortical minicolumns 
[Armstrong, 2004]. Subplate neurons are also abnormal because they do not express Map2 
[Kauffmann et al., 1995] and this results in impaired development of cortical minicolumns. 
Furthermore the gene, BDNF, regulates the development of C-R neurons in the cortex [Ringstedt et 
al., 1998]. Because BDNF is a target gene of MeCP2 (See “2.5 Target genes of MeCP2”), a 
mutation in MECP2 could interfere with the development of C-R neurons and thereby cortical 
minicolumns, which would lead to abnormal brain organization [Armstrong, 2004].   
 
                                                 
17
 Relating to nerve cells or fibres [CancerWEB, 2008]. 
18
 Subplate neurons are some of the first generated neurons in the mammalian cerebral cortex. These neurons disappear 
during postnatal development. They are important in establishing the functional maturation of the cerebral cortex.(see 
“Human Brain Development  
 31 MeCP2 and Rett Syndrome – The role of MeCP2 in brain dysfunction of Rett Syndrome 
Although the neuropathology of RTT still remains puzzling it is known that the mechanisms 
underlying the abnormalities of RTT brain most often is caused by MECP2 mutations and that the 
impaired MeCP2 function in RTT leads to what appear to be impaired maturation of many neurons, 
late developing neural pathways which leads to disrupted connections. 
 
4.2 RTT Mouse Models 
 
The mouse is the most usable and versatile animal for studying the mechanisms of normal and 
abnormal development of the human nervous system. It is far easier and ethically more correct to 
collect the necessary amount of brain tissue from mice than from humans. It has become an 
essential animal model especially in almost every field of neurobiology and experimental 
neuropathology [Goffinet & Rakic, 2000].  
 
There is to a certain extent similarity between brains of humans and mice, which makes mice usable 
for modelling human neuropathology. In mice, a large fraction of the genome, which involves 
40.000 genes, encodes approximately 75 million neurons and 25 million glia cells [Sutcliffe, 1988]. 
Homologs of these genes are also involved in coordinating the development of the human brain 
[Williams & Herrup, 1988]. The human brain generates about a thousand times more neurons, and 
the development and integration take more time because of its larger size and density. [Williams & 
Herrup, 1988]. This result in slow development in humans compared to mice. Notably mice brains 
are proportionally just as large as brains of human despite of the sizes of the two species [Williams, 
2000]. The overall embryonic development of human and mouse brain appear to be similar [Kuan et 
al., 2000], even though the mouse brain appears to be matured at birth, whereas the human brain 
experiences postnatal maturation [Shahbazian et al., 2002B].  
 
To get an understanding of the complex cause of RTT it has been necessary to generate mouse 
models that either are Mecp2-null mice or have a truncating mutation mimicking mutations of RTT 
patients. These mice make it possible to follow the life spanning development of the disease and to 
investigate the brain morphology of the RTT models. It is not given, however, that knowledge from 
such mouse models can be transferred directly to human patients because the genetic and 
developmental pattern of mice can be quite different from humans in that specific area. 
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Nevertheless if the symptoms and progression of disease in mouse models correlate with that seen 
in humans, the models can prove useful in the investigation of this disease mechanism. 
 
Different RTT mouse models have been created including Mecp2-null mice resulting in 
heterozygote females, hemizygote males and homozygote females, [Guy et al., 2001] and mice with 
a truncated form of Mecp2 resembling mutations seen in RTT patients. The latter model generated 
hemizygote males and heterozygote females [Shahbazian et al., 2002A]. In addition, the effect of 
Mecp2 over expression in mice has been tested [Collins et al., 2004]. Mecp2–null and truncation 
mice develop symptoms resembling those of RTT patients including abnormal gait, hindlimb 
clashing and irregular breathing and in one case smaller brain size and both smaller and more 
densely packed cell bodies and nuclei. This correlation between murine- and human symptoms 
indicates that Mecp2 mouse models are legitimate models for human RTT.  
 
4.2.1 Mecp2 and MeCP2 expression during early development is similar in 
mouse and human  
 
Laboratory analysis with mRNA in situ hybridization in mice has demonstrated that Mecp2 mRNA 
is present in the entire embryo and in the majority of neurons of the postnatal brain and to a greater 
extent in the olfactory bulb and hippocampus [Coy et al., 1999] If it is true that MeCP2 is present in 
all human tissues, it is quite surprising that RTT patients show symptoms that exclusively point to 
neuronal dysfunction.  
Shahbazian et al. [2002B] investigated the spatial and temporal distribution of Mecp2/MeCP2 
protein, during mouse and human development and the tissue-specific distribution of Mecp2 protein 
and Mecp2 mRNA in mice.  
 
The tissue-specific distribution of Mecp2 in mice 
The results of the tissue-specific analysis showed high levels of Mecp2 protein in brain, lung and 
spleen and a lower expression in kidney and heart. Mecp2 protein levels in liver, stomach and small 
intestine where almost undetectable. The same study investigated the Mecp2 mRNA distribution in 
humans and mice to find out whether the varying levels of protein expression were caused by 
varying transcription or posttranscriptional regulation. The results of the mRNA and protein 
analyses were incompatible, which indicates posttranscriptional regulation, probably tissue-specific. 
The fact that Mecp2 expression was relatively high in lung and spleen, and that it was also found at 
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low levels in kidney and heart is unexpected due to the neuronal specificity of RTT. The lack of 
somatic symptoms can be explained by two scenarios; other methyl-CpG binding transcriptional 
repressors (Mbd1 and Mbd2) (see “2.1 MeCP2 gene and product”) taking over in these somatic 
tissues or that there is no actual need for methyl-dependent silencing except in brain tissue 
[Shahbazian et al., 2002B]. The first scenario is possibly because Mbd1 and Mbd2 are known to be 
expressed in somatic tissue (see “2.1 MeCP2 gene and product”).    
To investigate this aspect further, it is useful to generate mouse models in which the gene-
repressing members of the Mbd-family proteins are knocked out separately in somatic tissue and in 
combination with Mecp2. This would give an idea of whether these proteins take over the work of 
MeCP2, and to which degree. Guy et al., [2001] created a mouse model by combining Mecp2-null 
mice and Mbd2-null mice. Onset of symptoms and mortality of the mice were not different from 
Mecp2-null mice. This indicates that Mbd2 is not the protein compensating for Mecp2 in somatic 
tissue, because that would give some additional somatic symptoms. Zhao et al. [2003] generated a 
Mbd1 mouse which appeared normal throughout life. However, when analysing the neurons they 
found reduced neuronal differentiation, -neurogenesis and increased genomic instability.  The lack 
of Mbd1 could be compensated for by Mecp2 and Mbd2 in CNS and somatic tissues respectively. 
Mecp2 could also, to some degree, compensate in somatic tissue.         
Mbd1-null mice should be combined with Mecp2-null mice to investigate whether Mbd1can 
account for the lack of somatic symptoms in Mecp2-null mice.  .     
 
 
Spatial and temporal Mecp2 and MeCP2 distribution in mice and human brains follow neuronal 
maturation 
The Mecp2 expression in mouse brain and the MeCP2 expression in human brain were followed at 
different stages of development. In both mice and humans Mecp2/MeCP2 was first expressed in the 
spinal cord and brainstem and later in the hippocampus and cerebral cortex, which correlates with 
the development of CNS from embryo to adult (see figure 9). First the spinal cord and brainstem 
develop and lastly the cerebral hemispheres. The course of maturation is well known in the cerebral 
cortex and this made it possible to determine that MeCP2 expression followed neuronal maturation. 
First to express MeCP2/Mecp2 were the C-R cells, then the deeper cortical layers and lastly the 
more superficial layers, which correlate with the maturation of neurons in the cerebral cortex (see 
“3 Human Brain Development”). In the brain of adult mice and humans, Mecp2/MeCP2 was 
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expressed in most neurons. In mice the increase in expression happened during embryonic 
development but in humans the increase continued until 10 years of age. This difference is most 
likely caused by inter-special differences and the continued increase in MeCP2 expression in 
humans could be ascribed to neuronal plasticity. Plasticity is, among other things, thought to 
involve neuronal physiology including the development of synapses [Insel, 1994]. 
 
 
 
Figure 9: Shows the distribution of MeCP2/Mecp2 (red dots) during development of CNS in humans (A) and 
mice (B). Wg refers to the week of gestation in humans and E refers to the day of embryonic development in 
mice. Common for mice and humans, Mecp2/MeCP2 first appears in the spinal cord, certain brainstem nuclei 
and in Cajal–Retzius neurons of the cerebral cortex. Mecp2/MeCP2 is expressed in midbrain, thalamus, 
cerebellum and the deep cortical layers. Mecp2/MeCP2 is later expressed in the basal ganglia, hypothalamus, 
hippocampus and finally in the superficial cortical layers [Shahbazian et al., 2002B]. 
 
Glucose metabolism has been shown to follow the developmental maturation of neurons, and 
thereby synaptogenesis, in humans. High levels are seen in the brainstem, thalamus and cerebellar 
vermis in the neonatal period. Synaptogenesis and glucose metabolism show a great increase in the 
period between birth and 4 years of age, then uniform levels until 10 years of age and finally a 
decline until it reaches the adult level (see “3 Human Brain Development”) [Chugani, 1998]. This 
supports that plasticity is the reason for the relatively late onset of RTT and that the symptoms 
appear when neurons are at a specific stage of maturation and can not proceed to the fully matured 
 35 MeCP2 and Rett Syndrome – The role of MeCP2 in brain dysfunction of Rett Syndrome 
state. The reason for this could be that MeCP2’s target genes that are important during neuronal 
development, but must be silenced in mature neurons otherwise proving harmful to normal 
function. The regression stage of RTT following a stage with some obtained motor and language 
skills could be explained by delayed onset of neuronal dysfunction [Shahbazian et al., 2002B].  
It could prove valuable to develop mouse models with brain-region specific deletions [Caballero & 
Hendrich, 2005]. This could clarify if MeCP2 is needed to the same degree in every region or if 
MeCP2 is more essential in some regions for a normal development. 
 
4.2.2 Mecp2 lack in mice causes RTT-like symptoms  
 
Mecp2 deficient mouse models displaying symptoms corresponding to RTT could be of vital 
importance in gaining an understanding of RTT pathology. Chen et al., [2001] investigated the 
effects of Mecp2 deficiency in mice by creating Mecp2-null mice. The study also analysed the 
effects of CNS specific deletions of Mecp2 at day 12 of embryonic development and postnatally in 
postmitotic neurons. To create mice with a CNS specific deletion of Mecp2 at day 12 of embryonic 
development they used a promoter and enhancer element from a gene encoding the protein Nestin. 
These are able to promote expression of Cre recombinase, which can delete Mecp2, only in CNS 
[Dubois et al., 2006]. Postmitotic deletion of Mecp2 in CNS were made possible by using a Cam-
Cre transgene which is a Cre transgene controlled by a Cam kinase 2 promoter. Cam kinase 2 is an 
abundant protein in neurons and is involved in diverse functions primarily in mature (postmitotic) 
neurons. Thus Cre recombinase is transcribed in postmitotic neurons and can delete Mecp2 [Mima 
et al., 2002]. The results of Chen et al., [2001] can point to whether RTT is a solely neuronal 
disorder and if it is caused by lack of MeCP2 during neuronal development or in mature neurons.    
 
Mecp2-null mice and brain specific deletion of Mecp2 
The Mecp2-null mice and the mice with Mecp2 prenatal deletion in the CNS had similar phenotype 
and seemed normal the first weeks after birth. They were able to reproduce but at the age of five 
weeks they began to develop nervousness, trembling, and abnormal breathing. 14 out of 35 mice 
became overweight and progressively more ill. In the late stages of the disease the mice became 
apathetic and began to lose weight. The mice died at approximately ten weeks of age. The 
heterozygote mutant female mice displayed normal behaviour for a longer period after birth (four 
months) whereupon they gained weight, became hypoactive and later developed ataxic gait. The 
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similarity of phenotypic outcome for Mecp2-null mice and in mice with brain specific deletion of 
Mecp2, supports RTT as being a neuronal disorder as no additional symptoms where registered in 
Mecp2-null mice [Chen et al., 2001]. However, it could be useful to create a mouse model in which 
only the somatic Mecp2 was deleted. The results could either confirm or dismiss the statement of 
RTT being an exclusively neuronal disorder.   
Some of the symptoms resembles the ones seen in RTT patients such ataxic gait, nervousness and 
abnormal breathing although the weight gain is not a normal symptom in humans. Reduced brain 
size and -weight accompanied by smaller and more densely packed cell bodies and nuclei in regions 
of the hippocampus, cerebral cortex and cerebellum were found in autopsy. This phenomenon has 
also been reported in RTT patients [Chugani, 1998] supporting the use of Mecp2 deficient mice as 
models for RTT patients. Guy et al., [2001] created the same models and reported development of 
symptoms in Mecp2-null mice between three and eight weeks of age. The animals began to loose 
weight in the later stage of the disease and died around 14 weeks old. The heterozygote females 
developed inactivity and hindlimb clashing at an age greater that three months and later developed 
unmistakable symptoms but some still seemed normal after a year. Like the other study, they found 
no differences in phenotypes between Mecp2-null mice and brain-specific deletion mice.  
The fact that heterozygote humans and mice experience a similar “normal” period of around 6 
months is surprising because MeCP2/Mecp2 was thought to follow maturation of neurons and mice 
mature at a much quicker pace than humans. This indicated that it may not be a developmental 
defect but that the resulting brain cells are functionally unstable [Guy et al., 2001].  
 
Deletion of Mecp2 in postmitotic neurons 
A critical aspect in RTT, still unresolved, is whether the syndrome is caused by dysfunction in 
neurons at time of symptom-onset or is a prenatal disorder which results in a delayed postnatal 
phenotype. To investigate this aspect, Chen et al., [2001] generated both male mice and 
heterozygote female mice with deletion of Mecp2 in postmitotic neurons. These mice appeared 
normal up to three months of age and then began to gain weight, develop ataxic gait and reduced 
activity at night time. The phenotype seems similar compared to Mecp2-null mice and mice with 
prenatal brain specific Mecp2 deletion, but with a later onset and less severe phenotype. Smaller 
neuronal cell bodies were again found in the cortex and hippocampus but not the cerebellum where 
the deletion did not occur. The results show that MeCP2 deficiency in postmitotic neurons is 
sufficient to develop RTT-like symptoms, which indicates that MeCP2 possesses a central role in 
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mature neurons. If RTT phenotype is caused by lack of MeCP2 in mature neurons rather than 
during development, this may imply that RTT can be reversed by postnatal introduction of MeCP2. 
[Chen et al., 2001]. 
 
Truncating mutations, mimic mutations seen in RTT-patients    
Shabazian et al. [2002A] generated mice displaying truncating mutations similar to those seen in 
RTT patients, because this is thought to create a more corresponding model. It was expected to 
result in a MeCP2 protein that was able to localize to heterochromatic chromosomal structures but 
lack the ability to recruit histone deacetylase complexes. The truncating mutation should be 
sufficient to result in RTT phenotype but still retain partial function of the protein (see figure 10). 
They succeeded in this and furthermore created surviving males with truncated mutations, 
displaying RTT-like symptoms. This made it possible to analyse behavioural phenotype and the 
progression of disease as the phenotype stabilizes like it is seen in human RTT.   
 
Figure 10: Shows the truncated Mecp2 protein in comparison to the wild type protein [Shabazian et al. 2002A, 
edited by Gede]. 
 
As expected, the male mice appeared normal at birth but then began to develop subtle symptoms at 
six weeks of age, where trembling could be felt when suspending the mice by their tails. The 
trembling gradually worsened and was apparent at the age of four months. 40 percent developed 
hunch back after five months (see figure 11). The fur became more oily and dishevelled than wild 
type mice at eight months of age. The mice experienced seizures, which also have been reported in 
RTT-patients. The majority of the Mecp2
trunc/y
 mice survived at least a year. The heterozygote 
females had a milder and more variable phenotype even after one year because of the extra X-
chromosome and probably skewed X-inactivation respectively. The mice had normal body weight 
and were fertile.  
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Figure 11: Shows development of hunch back in Mecp2
trunc/y
 mice in comparison with their wild-type littermates 
[Shabazian et al. 2002A, edited by Gede]. 
 
The mice were submitted to a number of tests to record their physical and social capacity in 
comparison to their wild-type littermates. The mutants, both males and females, displayed a small 
impairment in motor skills after 35 weeks of age and they showed lower activity levels possibly 
reflecting heightened anxiety. Younger mice did not exhibit impaired motor function but seemed to 
progressively loose their skills. Furthermore, the hypoactivity of the mutants corresponds to the low 
activity level of RTT patients. This loss of skills is also seen in RTT patients with purposeful hand 
movements (see “1 Rett Syndrome”). When suspended by their tails, they moved the forelimbs 
together quickly and repetitively sometimes holding them together for several seconds. This was 
also observed in the cages. This property could correspond to the stereotypic hand movements seen 
in RTT patients. The mutants also exhibited abnormal social behaviour as they did not spend time 
with wild-type mice which seemed to avoid the mutant mice. This could be explained by dominance 
by the mutants, although unlikely because of the motor impairment and lack of social awareness by 
the mutants or by active avoidance by the wild-type mice. The latter is likely because the mutants as 
mentioned were oily and clearly different from wild-type [Shabazian et al., 2002A]. The mice 
displayed normal spatial learning as they remembered where a subwater platform was placed in a 
pool of water as well as the wild-type mice did. Lastly, hyperacetylation of histone 3 was found in 
the cerebellum, cerebral cortex and spleen (where Mecp2 normally is abundant) of mutants, 
reflecting lack of Mecp2 to recruit deacetylation complexes. The brains of Mecp2
trunc/y
 were of 
normal size in oppose to RTT-patients. This can be explained by the fact that RTT-children begin to 
display symptoms between the age of six months and one and a half years at which point their brain 
is still increasing in size, whereas no symptoms in mice where noticed before six weeks when the 
head growth is almost done [Shabazian et al., 2002A].    
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4.2.3 Reversal of RTT-like defects in mice by introduction of Mecp2 
 
The neurons of RTT patients are defective but viable and that provides the prospect of reversal of 
the syndrome. If reversal is an option, it would mean a great leap for future therapeutic methods. 
However, this presupposes that there has not been made permanent damage to the neurons due to 
the lack of MeCP2 during development. MeCP2 could be essential to neuronal development during 
a specific time point. To investigate the possibility of reversal, Guy et al. [2007] created a mouse 
model with an inserted stop cassette which silences Mecp2 but with the possibility of reactivating 
the gene by cassette deletion.  
The Mecp2
stop/y 
males developed phenotype at the age of six weeks and died after about 11 weeks. 
The model appears to behave like other Mecp2-null mice, which was the aim. A transgene encoding 
Cre recombinase, fused with a modified estrogen receptor was then constructed. Cre recombinase 
makes it possible to remove the stop cassette but it stays outside the nucleus until tamoxifen (an 
estrogen analog) is injected and binds to the modified estrogen receptor, thus releasing the Cre 
recombinase. This allows the Cre recombinase to travel to the nucleus and delete the stop cassette, 
thereby reactivating Mecp2. When this was tested, five daily tamoxifen injections before the onset 
of symptoms caused reactivation in 75 to 81 percent of the brain cells. The injections proved to 
cause neurological symptoms and death in nine out of 17 mice. However the eight mice that 
survived did not develop symptoms, were fertile and showed wild-type survival. It was tested 
whether the death was caused by tamoxifen toxicity on control mice but they remained unaffected 
by the injections. Furthermore the effect of tamoxifen before death resembles the phenotype seen in 
Mecp2 over expression (see “4.2.4 Over expression of Mecp2 in mice”). A more gradual 
introduction of tamoxifen and thereby activation of Mecp2 by weekly injections showed to remove 
the toxic effect. The mice were scored (zero to two) for the presence of symptoms such as 
inactivity, abnormal gait, hindlimb clashing, tremors, irregular breathing and generally poor 
condition. The wild-type mice scored zero at all times whereas Mecp2
stop/y
 mice all displayed 
symptoms scoring from three to ten in the last four weeks of life and frequently became obese. Five 
out of six of the mice, in which Mecp2 was silenced, were partly rescued when given tamoxifen 
treatment. The mice lived 17 weeks and displayed mild symptoms close to wild-type and, in 
addition, obesity was lost.  
The results from this study show that the phenotypic outcome for mice with neurological symptoms 
can be improved by de novo expression of Mecp2. Restoration of the neuronal function can be 
explained by Mecp2’s target sites being determined solely be DNA methylation and that the 
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methylation system is maintained in mice lacking Mecp2 so when the protein is introduced it can 
retain normal function [Guy et al., 2007].  
 
4.2.4 Over expression of Mecp2 in mice causes improved motor skills and later 
RTT-like symptoms 
 
Before endogenous MeCP2 enhancement can be used as a future therapeutic method in RTT 
patients, it is necessary to look into the effects of over expressing the gene. This aspect was studied 
in Collins et al., [2004] by generating transgenic mice that expressed human Mecp2 and thereby 
obtained Mecp2 levels about twice as high as wild type mice. The mice were furthermore compared 
to mice with truncating mutations in Mecp2. 
The mice over expressing Mecp2 appeared normal at birth but developed abnormal phenotypes 
between 10 and 12 weeks of age (see figure 12). The abnormality was of varying severity 
depending on the degree of over expression. The symptoms were clasping of forelimbs when 
suspended by the tail, aggressiveness, hunch back and hypoactivity in the form of freezing 
behaviour. In addition the mice died prematurely.  
 
Figure 12: Shows the progression of symptoms in mice over expressing Mecp2 [Collins et al., 2004] 
 
Evaluation of axienty, hypoactivity aand cerebellar motor-and hippocampal learning  
Mice with an intermediate degree of heightened Mecp2 expression were submitted to a number of 
tests to evaluate anxiety, hypoactivity and cerebellar motor- and hippocampal learning. Because the 
progressive nature of the phenotype the tests were done between the ages of six and 20 weeks. 
There was no evidence of differences between wild type and Mecp2 over expression mice, but the 
latter showed behaviour indicating less anxiety. To evaluate motor coordination and cerebellar 
learning, a test was set up to see how long the mice could stay on a rotating rod. At sixth week there 
was no difference between the ability of wild type and Mecp2 over expression mice to stay on the 
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rod. At the test after ten weeks the transgenic mice, however, were significantly better, suggesting 
improved motor memory and perhaps cerebellar dependent motor learning. In a fear analysis, which 
assesses hippocampal- and amygdale-dependent learning, there was indication of improved 
hippocampal learning of the transgenic mice [Collins et al. 2004]. 
 
Synaptic plasticity   
The ability to learn is thought to be linked to synaptic plasticity and therefore Collins et al. [2004] 
investigated basal synaptic transmission, synaptic plasticity and long term potentiation in 
transgenic- and wild type mice. Basal synaptic transmission reflects the relationship between pre- 
and postsynaptic depolarization which represent the ability to conduct transmission. No difference 
between mutant- and wild type mice was seen in this test. The synaptic plasticity is recorded by a 
phenomenon named paired-pulse facilitation. It works by evoking two synaptic stimuli in a rapid 
pace and assessing the enhancement of the last response in comparison to the first. Transgenic mice 
showed improved synaptic plasticity compared to wild type. Long term potentiation is a form of 
plasticity that displays when synaptic responses are enhanced in response to a sequence of 
presynaptic stimulation and the enhancement can last for days [Bliss & Lømo, 1973]. Also in this 
analysis, mice over expressing Mecp2 experienced an enhancement of response (see figure 13). 
This indicates improved synaptic plasticity in mice over expressing Mecp2 and that the protein 
plays a central role in this plasticity. Electroencephalographic (EEG) traces showed abnormal 
spikes without any seizures following. By week 50, the seizures were frequent and so were the 
abnormal spikes. The spikes were now accompanied by akinetic
19
 seizures.   
                                                 
19
 Without movement (or without much movement) [MedicineNet, 2008]  
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Figure 13: Shows electroencephalographic traces for right (R) and left (L) hemisphere for wild-type and mice 
over expressing Mecp2 at week 20 and 50. 
 
Crossing of Mecp2-null mice with mice over expressing Mecp2 
The transgenic mice apparently seemed to exhibit enhanced motor memory, cerebellar- and 
hippocampal learning as well as synaptic plasticity around the age of 20 weeks but as the mice grew 
older (around 30 weeks) they began to display seizures, hypoactivity, spasticity, and hunch back. 
The animals ceased grooming themselves and eventually died. To verify that this was indeed caused 
by the over expression of Mecp2 and that human MeCP2 functions in mice Collins et al. [2004] 
crossed Mecp2-null mice with the mice over expressing Mecp2. Expression of human MeCP2 
rescued mice from symptoms of lack of Mecp2. Furthermore removal of the allele containing 
mouse Mecp2 rescued the mice from symptoms of over expressing Mecp2. This confirms that 
Mecp2 over expression caused the phenotype described above and that human MeCP2 has an effect 
in mice. 
 
Comparison of Mecp2-null- and mice over expressing Mecp2 
When comparing Mecp2-null- and the transgenic mice in question it is obvious that they have some 
properties in common. Both types obtain progressive neurological disorders, which appear after a 
normal period of development. Another study Luikenhuis et al. [2004] in which they also developed 
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transgenic mice over expressing Mecp2 supports the phenotype of a progressive neurological 
disorder. The similarities between phenotypes caused by lack- and over expression of Mecp2 are 
interesting because some patients displaying variant RTT have been shown to possess a twofold 
level of MeCP2 mRNA [Ariani et al., 2004].  But there are areas where they differ from each other. 
Mice with over expression of Mecp2 display improved motor skills and low anxiety whereas 
Mecp2-null mice exhibit the opposite. A reason for the harmful effect of too much MeCP2 could be 
that abundant MeCP2 repress genes without discriminating or repress its normal target genes 
without any regulation e.g. caused by limited amount of modifying enzymes. The results of this 
study show that the protein level of MeCP2 is highly regulated and this should be considered before 
beginning to use it as a therapeutic method for RTT patients. In addition, over expression of MeCP2 
due to gene duplications could be the cause of variant RTT in humans [Collins et al., 2004].    
Below are two tables which sums up the described mouse models (table5) and useful mouse models 
not created yet (table 6).  
 
Table 5: Shows the mouse models described in this paragraph. 
Mouse model Study Key point 
Mecp2 deletion [Chen et al. 2001], 
[Guy et al. 2001] 
Lack of Mecp2 in mice causes RTT-like symptoms 
Brain-specific Mecp2 
deletion 
[Chen et al. 2001], 
[Guy et al. 2001] 
RTT is a neuro-dependent disorder 
Brain-specific Mecp2 
deletion in postmitotic mice 
[Chen et al. 2001] Lack of Mecp2 in postmitotic neurons of mice is 
sufficient to cause RTT-like symptoms 
Mecp2 truncation [Shabazian et al. 
2002A] 
Truncating mutations in Mecp2 causes RTT-like 
symptoms in mice, and a more stable disorder than 
Mecp2-null mice. 
Replacement of Mecp2 [Guy et al. 2007] Gradual introduction of Mecp2 in Mecp2-null mice 
betters the phenotypes 
Mecp2 over expression [Collins et al. 
2004] 
Over expression of Mecp2 in mice causes enhanced 
motor skills but is eventually detrimental 
 
Table 6: Shows future mice models that would be useful.  
Future mouse models 
Brain region-specific 
Mecp2 deletion 
This could clarify if MeCP2 is needed to the same degree in every region 
or if MeCP2 is more essential in some regions for a normal development 
Deletion of Mecp2 in 
somatic tissue 
This could either confirm or dismiss the statement of RTT being an 
exclusively neuronal disorder.   
Deletion of the Mbd1 in 
somatic tissue combined 
with deletion of Mecp2 
This would give an idea of whether this protein takes over the work of 
Mecp2, and to which degree.     
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5 DISKUSSION 
 
Rett Syndrome is a neuronal disorder  
The fact that Mecp2 expression is relatively high in lung and spleen, and that it is also found at low 
levels in kidney and heart is unexpected due to the neuronal specificity of RTT. Furthermore, the 
fact that Mecp2-null mice do not experience additional symptoms in comparison to mice with brain-
specific deletion of Mecp2 supports that RTT is a neuronal disorder. The lack of somatic symptoms 
can, as mentioned, be explained by two scenarios; other methyl-CpG binding transcriptional 
repressors taking over the function of MeCP2 only in somatic tissue or that there is no actual need 
for methyl-dependent silencing except in brain tissue. However it seems unlikely that a lot of 
energy would be invested in producing the protein if it is not needed, even though there can be an 
evolutionary explanation to this. In addition, other proteins of the MBD family; MBD1 and MBD2 
have been shown to bind to methylated DNA and repress transcription, which support the scenario 
of other methyl-CpG binding transcriptional repressors taking over.  The mouse model created by 
combining Mecp2-null- and Mbd2-null mice, had no additional symptoms when comparing it to the 
Mecp2-null mice, which shows that Mbd2 is not the protein compensating for Mecp2 in somatic 
tissue. Mbd1, which is also expressed in somatic tissue, is still a possible compensator, and should 
therefore be tested in the same manner. It is interesting that Mbd1-null mice showed signs of 
reduced neuronal differentiation as well as genomic instability. The lack of neuronal differentiation 
is similar to the results seen in Mecp2-null mice which points to parallel functions and that Mecp2 
also might be involved in genomic stabilization.   
 
The Mecp2 expression in somatic tissues and lack of somatic symptoms can also be explained by 
differences in the abundance of the two isoforms of MeCP2; MeCP2A and MeCP2B. These two 
isoforms are expressed differently in the body. It has been shown that MeCP2A is more abundant in 
somatic tissues while MeCP2B is seen mostly in brain tissue. MeCP2A includes exon 2, 3 and 4 
while MeCP2B includes exon 1, 3 and 4. Mutations in exon 1 are known to cause RTT, while no 
mutations have ever been found in exon 2 which makes MeCP2B the pathogenic protein. If it is 
correct that MeCP2B is the predominant protein in the brain, compared to MeCP2A, this can 
explain why a mutation in exon 2 would not result in a somatic-dependent phenotype. Nevertheless 
it would not explain why mutations in exon 3 and 4 do not result in any somatic symptoms. Focus 
on the type of isoform expressed during development of the human brain and other tissues might 
give an insight to diverse functions of the two isoforms. It would be an idea to make a mouse model 
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with deletion of exon 2 in Mecp2 and see if symptoms would appear. This could show if MeCP2A 
contributes to the phenotype of RTT. In addition, MeCP2A might have a slightly different function 
than MeCP2B in somatic tissue, which could be compensated by other proteins than those in the 
MBD-family, and this should be investigated further.                    
 
MeCP2 expression is important for the neuronal development and maturation 
In mice the increase of Mecp2 expression in brain happened during embryonic development but in 
humans the increase continued until 10 years of age. This difference is likely to be caused by inter-
special differences. The continued increase of MeCP2 expression in humans could reflect synaptic 
plasticity, which occurs mainly from the age of one to ten years in humans, while this primarily 
takes place in the prenatal period in mice. However the fact that RTT symptoms first appear around 
six month postnatally in both heterozygote humans and mice do not correlate with the idea that 
MeCP2 is needed for reaching of the full maturated state of the neurons because the mice brain 
would be fully matured soon after birth. This indicated that RTT may not be due to a failure of 
reaching the fully matured state but that the resulting neurons are functionally unstable in the lack 
of MeCP2. However, the increase in glutamate receptors in RTT girls until the age of eight could 
reflect a persistence of the immature state of neurons as this increase normally is constricted to the 
first months of postnatal life. This speaks for MeCP2 as being important in maturation of neurons.  
 
Any instability of neurons caused by lack of MeCP2 could either be a permanent damage to the 
neurons or can be reversed by the introduction of MeCP2 later on. The fact that some Mecp2-null 
mice can avoid RTT-like symptoms when transcription of Mecp2 is reactivated indicates that in 
these mice no permanent damage has been made on the neurons in early development. 
Nevertheless, some of these mice were not completely free of symptoms, which could be a sign of 
some permanent neuron damage. Even if this is the case, the study emphasized that MeCP2 plays an 
important role in the function of mature neurons. This is further supported by results showing that 
Mecp2 deficiency in postmitotic neurons is sufficient to develop RTT-like symptoms in mice. The 
symptoms had a later onset and the phenotype appeared milder and therefore a role of MeCP2 in 
premitotic neurons can not be ruled out.        
    
The theory that the symptoms of RTT is caused by stunted synapse development, and thereby that 
MeCP2 normally plays a role in this, is supported by several facts; synaptic- and dendritic growth is 
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reported to be reduced in RTT brains, genes important in synapse development are consistently 
down regulated in RTT brains and mice over expressing Mecp2 display an initial improvement in 
synaptic plasticity. Synaptogenesis and glucose metabolism are increased in the period between 
birth and 4 years of age. This supports that plasticity is the reason for the relatively late onset of 
RTT if it results in symptoms first appearing when neurons are at a specific stage of maturation and 
can not proceed to the fully matured state. The reason for this could be that the target genes of 
MeCP2 are important during neuronal development, but must be silenced in mature neurons 
otherwise proving detrimental to normal function. The fact that several genes relating to synapse 
development is down regulated in RTT brains could be caused by mutant MeCP2 wrongfully 
“leaving on” some genes responsible for the repression of these synaptic genes. Furthermore, it has 
been suggested that MeCP2 also works as an activator, which could result in down regulation of the 
genes in RTT brains. The initial normal development indicates that the synaptic genes are not 
needed in prenatal development and normally are repressed as the symptoms first appear later on. 
This does not correlate with what is known about brain development because production of 
synapses is great prenatally. The regression stage of RTT following a stage with some obtained 
motor and language skills could reflect a great need for MeCP2 at the specific time point of 
regression or it could be a delayed response to an early disruption of normal neuronal development. 
The latter could explain why the repression of synaptic genes results in RTT phenotype in late 
infancy and not initially. Furthermore a deceleration of brain growth is already seen after 3-4 
months which precedes the onset of symptoms. 
         
The normal increasing expression of MeCP2 from conception until adolescence could reflects 
maturation of neurons, synaptogenesis, development of dendritic branching and prenatal synaptic 
plasticity. This means that lack of functional MeCP2 during this period would cause stunted growth 
of dendrites and synapses. Furthermore the emerging of symptoms such as deceleration of head 
growth and delayed motor skills and speech coincides with synapse proliferation in the cerebral 
cortex of humans. This is supported by reported reduction of MAP2, important for dendritic 
branching, in the motor and frontal cortex of RTT brains.  
 
Over expression and lack of MeCP2 cause similar symptoms 
There it is an ongoing discussion about what aspect of MeCP2’s function is responsible for the 
phenotype arising from mutations in MeCP2. In mice, RTT-like symptoms arise from lack of 
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functional Mecp2. However, mice over expressing Mecp2, and Mecp2-null mice experience a 
similar neurological disorder, which progressively worsen over time. In addition there is seen a 
normal period of development after birth for both mice. This normal period does not correlate with 
the explanation of MeCP2 being redundant in early development as this most likely would result in 
symptoms in mice over expressing Mecp2. It more likely indicates that the phenotype is a delayed 
response of early disruption of MeCP2 function.  
 
The similarity in phenotypic outcome from over expression and lack of Mecp2 correlates with RTT 
patients showing an atypical form having a duplication of MECP2. However, there are some 
differences in the phenotypes displayed. Mice over expressing Mecp2 exhibit initial heightened 
motor skills and synaptic plasticity which supports the theory of MeCP2 being perhaps indirectly 
involved in synapse development and the function of noradrenergic and serotonergic neurons in the 
brainstem responsible for locomotion. Ultimately, the mice began to experience akinetic seizures, 
different from the seizures in mice lacking Mecp2, and they died prematurely which reflects the 
harmful effects of abundant MeCP2. The fact that about half of the Mecp2-null mice died when 
treated with tamoxifen, which reactivated transcription of Mecp2, emphasizes the danger of too 
much MeCP2 too fast. When the tamoxifen treatments were given more gradually the mice did not 
die. This indicates that the transcriptional or posttranscriptional regulation of MeCP2 is highly 
regulated, and a big boost of Mecp2 is detrimental to mice and supposedly also to humans. It is 
notable that mice over expressing Mecp2 do not spontaneously die like the mice treated with 
tamoxifen. The mice over expressing Mecp2 had a 2 fold level of the protein which the mice to a 
certain degree could survive. The mice that died may have obtained a level much higher. The 
detrimental effects of the over expression could be caused by unregulated repression or possible 
activation of Mecp2’s target genes or repression of additional genes, even though it seems 
implausible that Mecp2 should obtain the property of repressing other genes because of its 
abundance. The over-repression of MeCP2’s target genes can reflect inadequate levels of regulating 
factors. When gene repression carried out by MeCP2 becomes unregulated the MeCP2 pathway 
could possibly be compromised. That is, the symptoms could reflect either unregulated repression 
of Mecp2’s target genes, or disruption of gene silencing because of a non-functional pathway 
system. 
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When analyzing the symptoms of the mice over expressing Mecp2, their initial improvements in 
motor skills indicate that gene-repression carried out by Mecp2 is functioning initially but the 
forelimb clasping happening around week 12 is similar to what is seen in mice lacking functional 
Mecp2. This could reflect arising of dysfunction of the mature brain around that time because of 
disruption of the Mecp2 pathway. The differences in phenotypes such as in the nature of the 
seizures can be explained by the presence of Mecp2 during prenatal development in the mice over 
expressing Mecp2. This indicates that mice over expressing Mecp2 experiences disturbance of the 
gene silencing mechanisms as a result of a period with excess Mecp2. This speaks for a role of 
MeCP2 during prenatal development and that presence of the protein during this time followed by 
later disturbance result in RTT symptoms that are milder than otherwise.     
 
Correlation between abnormalities observed in RTT brains and RTT symptoms 
The stereotypic hand movements, breathing abnormalities and occurrence of seizures exhibited by 
RTT patients indicate that excitatory synaptic activity may be affected by the lack of MeCP2. This 
correlates with the findings of increased glutamate receptors in RTT girls under the age of eight 
years, and signs of elevated levels of glutamate. Usually densities of the glutamate receptor subtype, 
NMDA, remain high the first months of postnatal life and then decrease. Thus the higher levels in 
the young RTT patients continuing to the age of eight years can be interpreted as persistence of the 
immature state. Furthermore BDNF, which is a target gene of MeCP2, has a positive effect on the 
survival of seronergic neurons which is important for maintenance of a mature phenotype.    
Synapses that use the excitatory neurotransmitter glutamate play an important role for movement 
and breathing, correlating with the impairment of locomotion and abnormal breathing of RTT 
patients. The pruning of excessive synapses normally happens around age 10 when the decrease of 
glutamate receptors in RTT patients also are seen. This could result in the relative stabilization of 
symptoms including seizures, which is seen in stage 4 in RTT, because the excitatory stimulation 
consequently decreases.  
   
When analyzing the emergience of symptoms in RTT patients the impairment of locomotion seems 
to be the initial symptom especially apparent in the delay or absence of crawling. Locomotion is 
provoked by innervation of noradrenergic and serotonergic neurons in the brainstem which are 
known to be important in humans for the postnatal development of brain. This is supported by the 
fact that early lesions of noradrenergic neurons cause deceleration of head growth which is seen in 
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RTT patients. Furthermore MeCP2 is expressed quite early in the brainstem containing these 
aminergic neurons which is usually thought to reflect the need for the protein in normal 
development. The hand wringing and loss of useful hand use could be caused by dysfunction of 
dopamine neurons, which play a central role in the control of voluntary movement. The aminergic 
neurons of the brainstem modulates the function of dopamine neurons which could explain the 
secondary symptoms. However, it is necessary to investigate whether a change in density of these 
neurons are seen in RTT brains to verify that this is actually the cause of impaired motor skills, 
seizures and stereotypic hand movements.   
 
The size of cortical minicolumns is reduced in RTT patients and in autistic patients. This could be 
responsible for the overlapping phenotypes of these disorders such as the withdrawal and lack of 
eye contact. Furthermore MECP2 mutations have been identified in autistic patients, which support 
that defect minicoloumns could be a direct result of mutations in MECP2. Formation of the mini 
columns depends on the C-R- and subplate neurons and both types appear to be compromised 
because of the lack of MeCP2, which is concluded for different reasons. C-R neurons are normally 
some of the first neurons to express MeCP2, again reflecting the need for MeCP2 for normal 
development. Subplate neurons in RTT brains showed a reduced level of MAP2. This could result 
in impaired mini columns having the consequence of disrupted organization of neuronal 
connections causing autistic symptoms.    
 
Summing up  
 
RTT is a neuronal disorder, but the presence of MeCP2 in somatic tissue raises questions about 
whether the lack of MeCP2 in somatic tissue can contribute to the symptoms of RTT. Some 
knowledge implies that this is not the case. The fact that the brain is the only organ which is visibly 
affected in RTT patients, that symptoms of brain specific Mecp2 deletion is not milder than those of 
Mecp2-null mice, that MeCP2B, the disease causing isoform, is most abundant in brain tissue and 
that MeCP2 target genes primarily are involved in neurodevelopment or –function, all indicates that 
only lack of MeCP2 in brain causes the development of RTT. However, it can not be ruled out that 
lack of MeCP2 in somatic tissue can cause some RTT symptoms, and that functions of the 
MeCP2A isoform should be further investigated, to determine this.  
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The expression of MeCP2 has been shown to follow the maturation of neurons, and may therefore 
be important for the developmental process of neurons. Nevertheless RTT symptoms first appear  
around six months of age in both human and mice  The late onset of symptoms and the fact that 
symptoms appear at similar time points in both human and mice, despite different maturation 
patterns, indicates that onset of symptoms does not reflect that MeCP2 is needed to fulfill 
maturation. The late onset could be explained by delayed response of neuronal damage or it may be 
possible that the symptoms can not be observed before, because it simply is not possible to detect 
lack of speech and impaired motor skills.  
The fact that mice with postmitotic deletion of Mecp2 show a mild RTT-like phenotype indicates 
that Mecp2 is needed for both the early development of neurons and the function of mature neurons.   
 
Studies of mice over expressing Mecp2 collectively indicates that changes in the level of MeCP2 
results in disruption of neuronal function, and that elevated levels of MeCP2 could result in an 
overheated system which puts normal gene regulation out of function. This can explain some 
similarities in symptoms of mice lacking and mice over expressing Mecp2. In addition mice over 
expressing Mecp2 exhibit initial heightened motor skills and synaptic plasticity which supports the 
theory of MeCP2 being directly or indirectly involved in synapse development, dendritic branching 
and development of motor skills.   
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6 Conclusion 
 
The gene MECP2 regulates transcription of several other genes by repression and possibly 
activation. Expression of MeCP2 is important in maturation of neurons and function of mature 
neurons. Genes that appear to be affected are involved in synapse- and dendrite development. 
Mutated MECP2 results in reduced brain size in frontal and temporal region, stunted neuronal 
connections, dense packing of neurons and diminished nuclei size. The symptoms of seizures and 
stereotypic hand movements are likely caused by elevated excitatory stimulation in the frontal 
cortex, and basal ganglia caused by either elevated levels of excitatory neurotransmitters, such as 
glutamate, or glutamate receptors seen in younger RTT patients. The decreased density of glutamate 
receptors, that sets in around the age of eight years can explain the relative stabilization of 
phenotype around this time. The initial symptom of impaired locomotion is caused by disruption of 
aminergic neurons in the brainstem. Further investigation is needed to understand the cause of the 
distinct RTT symptoms and progression of the disorder. RTT mouse models are useful in this 
investigation because they display symptoms similar to RTT patients. However, the difference in 
rate of maturation of neurons should be taken into account when interpreting the results.                 
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7 Closing remarks 
 
Future mouse models referred to in this project focuses on determining whether MeCP2 has a 
function in somatic tissue, and whether MBD1 compensates for this. Furthermore it is very 
important to detect any brain regional variations in acquirement of MeCP2 which may point to 
specific target genes of MeCP2.  This could be done with deletion of MeCP2 in certain regions of 
the brain and detection of distinct symptoms. Before the pathology of RTT can be resolved, a lot of 
investigation must be carried out – especially of MeCP2’s target genes and the functions of these. In 
addition, knowledge about the regulation of MeCP2 and appropriate levels of the protein is essential 
if introduction of MeCP2 is to be used as a future therapeutic method. This was demonstrated by 
Guy et al. [2007] and Collins et al. [2004] as they investigated the effect of reactivation and over 
expressing MECP2 respectively. Also the time point of MeCP2 introduction should be considered 
in respect to the acquirement of MeCP2 for example during development of synapses and dendritic 
branching.         
 
When reviewing the clinical phenotype of RTT patients the target genes of MeCP2 appear to be 
constricted to the brain which is in accordance with epigenetic modification being important for 
neuronal maturation [Persengiev & Kilpatric, 1996]. MeCP2 has also been implicated in the 
regulation of a number of imprinted genes [Drewell et al., 1996] and a great proportion of identified 
imprinted genes are highly expressed in the CNS [Davies et al., 2004]. Epigenetic modification of 
gene expression can represent an extra layer of regulation which makes it difficult to predict the 
outcome of a mutation. It can protect a person from any phenotypic outcome if the gene carrying 
the mutation is silenced. This can be the case if the gene is an imprinted gene which is not supposed 
to be expressed when inherited either maternally or paternally. Furthermore the phenotypic outcome 
can be affected by X-chromosome inactivation in females, if the mutated gene lies on the X-
chromosome. Mutations in a gene executing epigenetic regulation, like MeCP2, can have 
widespread consequences which makes it vital to obtain knowledge about the target genes of the 
modification in question. 
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Appendix I 
 
Epigenetics 
 
Epigenetics are changes in gene expression that do not involve changes in DNA sequence. The gene 
implicated in RTT syndrome, MECP2, is involved in gene repression in an epigenetic manner 
which makes it relevant to look into this form of regulation. Furthermore the expression of the 
syndrome is affected by epigenetics.  
For a long time, the genomic sequence was thought to be the sole determinant of phenotypic 
characteristics and propensity to disease. Naturally, hereditary diseases were blamed on mutations, 
which change the genomic sequence. While this is often the case, an extra level of regulation of 
gene expression was discovered – Epigenetic modification.  
Developmental biologist, Conrad H. Waddington treated small flies of the species Drosophila 
pupae with heat, and the result was transformed wing vein patterns which continued long after the 
stimuli were removed. This demonstrates how environmental factors can alter the phenotype at 
critical developmental time points. Epigenetic modification of gene expression can be seen as the 
adaptation of an organism to its environment. When the adaptation correlates with the future 
demands, the modification is an advantage. If not, it could possibly promote the risk of disease. 
Most human organs do not reach maturation until weeks or even years after birth which allows for 
prolonged impact of the environment. This impact could be too much or too little nourishment or 
exposure to infection, hormones, drugs or toxins. [Tang & Ho, 2007]. There are different types of 
epigenetic modification, all of which have the important function of regulating gene expression 
after requirement.   
Genomic imprinting refers to modification of gene expression depending on their parental origin – 
that is, some genes are only expressed when inherited from a sperm cell and some are expressed 
only when inherited from an egg cell. About 35 imprinted genes are recognized in humans. The 
biological significance of imprinting has not yet been established but several theories have emerged 
one of which claim that imprinted genes are important in embryonic growth and development 
[Brøndum-Nielsen & Pedersen, 2001]. Another type of epigenetic modification is the X-
chromosome inactivation that takes place in females – one of the X-chromosome in each cell is 
randomly inactivated during early development. A third type of epigenetic modification is gene 
silencing. As different tissues need to express different genes at certain time points, a regulation of 
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DNA transcription is vital for normal development and maintaining health. This is partly done 
through DNA-methylation in cooperation with a class of proteins called methyl-CpG binding 
proteins (MeCPs) and histone modifications.  
MeCP2 repress transcription of certain genes by binding to methylated DNA and recruiting histone 
deacetylases and histone methyltransterases as well as hindering the presence of transcription 
factors (TFs), (see “2.2 The Mechanism of MeCP2 Repression”). In addition RTT itself is affected 
by X-chromosome inactivation because it is an X-linked disorder. The phenotype of a RTT patient 
is therefore highly affected by X-chromosome inactivation since the patients are mostly girls which 
are almost exclusively heterozygote for the syndrome. Furthermore, the target genes of MeCP2 are 
especially thought to be imprinted genes [Shahbazian & Zoghbi, 2002].  
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Appendix II 
 
Divisions and functions of the brain 
 
 
The different symptoms displayed in RTT patients, may be a result of defects in certain areas of the 
brain, which can be caused by MeCP2 deficiency. This is supported by the findings of MeCP2 
target genes that encode neural development and function. The brain is part of the CNS and controls 
a variety of body functions. It consists of the brainstem, the cerebellum and forebrain, where the 
brainstem includes the medulla oblongata, pons, midbrain and reticular formation, and  the 
forebrain is composed of the diencephalon and the cerebrum (see table I). Furthermore 
cerebrospinal fluid is filling the ventricles and surrounding the brain and spinal cord. 
 
Tabel I: this table sums up the functions of the different brain areas and shows their location [Seeley et al.,2008] 
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Brainstem 
The brainstem is responsible for a range of essential functions, including reflexes vital for survival, 
for which reason damage to small areas of the brainstem often results in death. As mentioned above 
the brainstem consists of a range of centers, where the medulla oblongata, also simply referred to 
as the medulla, is responsible for autonomic functions, such as respiration, blood pressure, 
swallowing, vomiting, defecation and other reflexes (See table I).  
The pons located superior to the medulla, relay information from the cerebrum to the cerebellum. 
This division also contains a sleep center and a respiratory center, which cooperates with the 
respiratory center of medulla to control the respiratory movements (See table I).   
The midbrain, also referred to as the mesencephalon, is located superior to the pons. It is involved 
in visual reflexes, which controls the movement of head, eyes and body, and is also a part of the 
auditory pathway in the CNS (See table I). 
 
Cerebellum 
The cerebellum, is also referred to as the little brain, consists of an outer cell layer, the cerebellar 
cortex, white medulla in the middle and nuclei in the center. The cerebellum can be divided into 
three parts; a small inferior part, the flocculonodular lobe, a narrow central vermis, and two 
hemispheres. The cerebellum is important for the fine motor coordination and controlling of the 
locomotion, balance and posture. These functions are preformed in accordance to the information 
the cerebellum receives from muscles, joints, skin, eyes, ears, viscera, and the centers of the brain 
responsible for controlling movements. The cerebellum is also implicated in planning, practicing 
and learning complex movements (See table I).   
 
Forebrain 
The cerebrum is divided into a right and a left hemisphere, and consists of an outer shell of gray 
matter, the cerebral cortex, and an inner layer, the white matter, which primarily consists of 
myelinated fiber tracts. These tracts consist of nerve fibers that connect different areas within a 
hemisphere. The cerebral cortex is separated into four lobes: the frontal, occipital, temporal and 
parietal (see “4.1 The Neuropathology of RTT” figure 7). The subcortical nuclei are heterogeneous 
groups of gray matter deep within the hemispheres. The predominant among these are the basal 
ganglia, which are important for controlling posture, movement and more complex aspects of 
behavior. 
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The diencephalon, is the central core of the forebrain, is located between the brainstem and the 
cerebrum, and consists of thalamus, subthalamus, epithalamus and hypothalamus.  
Thalamus is a mass of gray matter that forms the larger dorsal subdivision of the diencephalon. It is 
considered as sensory relay center, because sensory inputs go through this center before it is 
projected to an appropriate area of the cerebral cortex via three nuclei. The thalamus also influences 
the mood and actions associated with strong emotions such as rage and fear. The epithalamus 
responds to smell and are involved in emotional and instinctive responses to odors, and the 
hypothalamus located below thalamus contains several nuclei and tracts, and controls the 
homeostasis and the regulating of endocrine system.  
Parts of the cerebrum and diencephalon are classified together in a functional system called the 
limpic system. These interconnected brain structures include thalamus, hypothalamus, temporal 
lobe (containing amygdaloid nucleus), part of the frontal lobe cortex, hippocampus, olfactory bulb 
and fiber pathways that connect them. (See figure I).        
 
 
Figure I: Structures of the limbic system is shown in a partially transparent view of the brain [Widmaier et al. 
2008]. 
 
 
 
